Document:

Second Amended and Restated Employment Agreement

 Exhibit 10.1 
 Second Amended and Restated Employment Agreement 
 by and between Immunomedics, Inc. and

 Dr. David M. Goldenberg 
 Dated as of December 17, 2008 

 TABLE OF CONTENTS 
  

					
	 	  	 	  	Page
			
	 1.
	  	Employment	  	2
			
	 2.
	  	Term	  	2
			
	 3.
	  	Duties	  	3
			
	 4.1.
	  	Compensation	  	5
			
	 4.2.
	  	Additional Incentive Compensation	  	6
			
	 5.
	  	Vacation and Fringe Benefits	  	13
			
	 6.
	  	Research Contracts or Grants	  	14
			
	 7.
	  	Prior Inventions and Discoveries	  	14
			
	 8.
	  	Arbitration	  	17
			
	 9.
	  	Restrictive Covenants	  	17
			
	 10.
	  	Termination	  	23
			
	 11.
	  	Decisions and Determinations of the Board	  	27
			
	 12.
	  	Cooperation with Immunomedics After Expiration or Termination	  	27
			
	 13.
	  	Payment and Benefits on Termination or Expiration	  	28
			
	 14.
	  	Legal Costs	  	36
			
	 15.
	  	Parties in Interest	  	36
			
	 16.
	  	Notices	  	36

					
	 17.
	  	Governing Law	  	38
			
	 18.
	  	Captions; Word Meanings	  	39
			
	 19.
	  	Miscellaneous	  	39
			
	 20.
	  	Binding Effect	  	40
			
	 21.
	  	Entire Agreement	  	40
			
	 22.
	  	Severability	  	40
			
	 23.
	  	Survival of Provisions	  	40
			
	 24.
	  	Counterparts	  	41

  

 3 

 SECOND AMENDED AND RESTATED 
 EMPLOYMENT AGREEMENT 
 This SECOND AMENDED AND RESTATED EMPLOYMENT
AGREEMENT (“this Agreement”) is made and entered into as of December 17, 2008, by and between IMMUNOMEDICS, INC., a Delaware corporation with its principal office and place of business in Morris Plains, New Jersey (“Immunomedics”
or the “Company”) and DR. DAVID M. GOLDENBERG, an individual presently residing in Mendham, New Jersey (“Dr. Goldenberg”). 
 PREMISES 
 WHEREAS, Dr. Goldenberg founded Immunomedics in 1982 and continuously since that time, has served as
the Chair of its Board of Directors, as an executive of the Company, and as a significant shareholder of the Company; and 
 WHEREAS,
Dr. Goldenberg invented and developed virtually all of the technology, and obtained the patents, on which Immunomedics’ business is based; and 
 WHEREAS, Immunomedics and Dr. Goldenberg entered into an Employment Agreement dated as of the 15th day of May, 1983 (the “Initial Agreement”), which the parties amended and in certain instances restated
in 1998 and 2003 (collectively, the “Amended Agreements”); and 
 WHEREAS, the parties entered into an Amended and Restated
Employment Agreement effective as of July 1, 2007 (the “Amended and Restated Agreement”), which amended and restated in their entirety the Amended Agreements; and 
 WHEREAS, the parties entered into an amended to the Amended and Restated Agreement on January 31, 2008 (the “2008 Amendment”); and

 WHEREAS, the parties reached agreement on the terms of this Agreement, to amend and restate the Amended
and Restated Agreement, as amended by the 2008 Amendment, in their entirety; 
 NOW, THEREFORE, in consideration of the mutual promises set
forth herein, the parties, intending to be legally bound, agree to amend and restate the Amended and Restated Agreement, as amended by the 2008 Amendment, and incorporate them in their entirety into this Agreement, as follows: 
 1. Employment. Immunomedics agrees to continue the employment of Dr. Goldenberg, and Dr. Goldenberg accepts such continued employment,
upon the terms and conditions set forth in this Agreement. 
 2. Term. Unless earlier terminated by either party pursuant to
Section 10, this Agreement will continue for a four (4) year period following July 1, 2007 (through June 30, 2011) (the “Initial Term”). This Agreement automatically shall renew for additional one (1) year periods
following the end of the Initial Term or any additional one (1) year period, unless either party gives written notice to the other party at least ninety (90) days prior to the end of the Initial Term, or unless terminated earlier pursuant
to Section 10 of this Agreement. For purposes of this Agreement, “Term of this Agreement” is defined to include both the Initial Term and any renewal periods collectively. For purposes of this Agreement, “Contract Year” is
defined as a period of twelve (12) consecutive calendar months beginning on July 1, 2007, or any anniversary thereof, and ending on the last day of the twelfth month thereafter. For purposes of this Agreement, “Term of
Employment” shall mean the length of Dr. Goldenberg’s total employment from original hire through the end of the Initial Term, plus any renewal periods within the Term of this Agreement, or through the date of termination if this
Agreement is terminated during the Initial Term pursuant to Section 10. 
  

 2 

 3. Duties. 
 (a) Description. Throughout the Term of this Agreement, Dr. Goldenberg shall serve as Chief Scientific Officer and Chief
Medical Officer of Immunomedics and shall perform such duties in these roles, which are commensurate with Dr. Goldenberg’s expertise, experience, roles fulfilled within the Company, and professional standing and the needs of the Company
from time to time, as the Board of Directors of Immunomedics (the “Board”), in consultation with Dr. Goldenberg, may determine from time to time. The Board may assign specific duties to Dr. Goldenberg after a review of
Immunomedics’ needs. Dr. Goldenberg will report directly to the Chief Executive Officer, and will continue to be accountable directly to the Board throughout the Term of this Agreement. Immunomedics reserves the right, subject to
Section 10(f) below, to modify, but not diminish, the nature and scope of Dr. Goldenberg’s duties to meet the Company’s changing needs, provided that such duties and level of authority shall remain commensurate with
Dr. Goldenberg’s expertise, experience and professional standing. If elected to such positions, Dr. Goldenberg may serve as a member of the Board, and as an executive officer and director of any subsidiary or affiliate of or successor
to Immunomedics and, in the Board’s discretion, may be paid additional, reasonable compensation for such services. 
 (b)
Best Efforts. Throughout the Term of this Agreement, Dr. Goldenberg shall faithfully, industriously and to the best of his ability, experience and talents, perform all of the duties contemplated by this Agreement and in accordance with
his fiduciary duties as an officer and director of the Company. In the course of performing such duties, Dr. Goldenberg shall cooperate fully, to the best of his ability, with the Board and all officers, agents and employees of Immunomedics in
all matters connected with the business of Immunomedics. 
  

 3 

 (c) Extent of Duties. Dr. Goldenberg shall devote such time to Immunomedics
as is reasonably necessary to fulfill the duties contemplated by this Agreement. Notwithstanding any language to the contrary, Immunomedics acknowledges and authorizes Dr. Goldenberg to perform the following roles and to dedicate the time
necessary to perform such roles, the scope of which Immunomedics acknowledges and agrees does not materially interfere with his performance of duties directly for Immunomedics: 
 (i) To serve as a member of the Board of Trustees of and to be employed (including without limitation as the President and/or Chief
Executive Officer) by the Center for Molecular Medicine and Immunology (a/k/a Garden State Cancer Center) or any of its subsidiaries, affiliates, successors or any non-profit substitute entity (collectively the “Center”), provided, that
any such subsidiary, affiliate, successor or non-profit substitute entity agrees to undertake all of the obligations of the Center pursuant to any existing or future license, proprietary rights or other equivalent agreement between Immunomedics and
the Center. 
 (ii) To serve as a member of the Board of Directors of and to be employed (including without limitation as an
executive officer) by the Company’s majority-owned subsidiary, IBC Pharmaceuticals, Inc. (“IBC”). 
 Immunomedics acknowledges
that Dr. Goldenberg shall be entitled to spend such time as is necessary to fulfill his duties for the Center and IBC, provided that such duties do not materially interfere with his ability to perform any of his obligations under this
Agreement. Such activity on behalf of the Center, and his activity on behalf of IBC to the extent consistent with the provisions hereof, shall not be deemed a breach of this Agreement. Any salary, fees or other income paid by the Center and IBC to
Dr. Goldenberg in his respective capacity in each such entity shall be the property of Dr. Goldenberg and shall not diminish the compensation due him hereunder. 
  

 4 

 4.1. Compensation. 
 (a) Base Salary. In consideration for services rendered by Dr. Goldenberg pursuant to this Agreement, Immunomedics will pay
Dr. Goldenberg a base salary at the rate of Five Hundred Thousand Dollars ($500,000.00) per Contract Year, payable in accordance with the Company’s regular payroll procedures (the “Base Salary”). The Board or the Compensation
Committee of the Board (the “Compensation Committee”) may review Dr. Goldenberg’s Base Salary annually for appropriate increases, pursuant to the Company’s standard performance review policies for senior level executives.

 (b) Annual Bonus. Throughout the Term of this Agreement, Dr. Goldenberg will be eligible to participate in the
Company’s incentive compensation plan for senior level executives (the “Incentive Plan”) in accordance with the terms of the Incentive Plan. The Company reserves the right to amend or rescind its Incentive Plan at any time in its
discretion, but will provide Dr. Goldenberg written notice of any changes at the same time and in the same manner as other Incentive Plan participants as may be required by law or regulation. In connection with his participation in the
Incentive Plan, Dr. Goldenberg will be eligible to receive an annual discretionary bonus, as determined by the Compensation Committee, based on its assessment of Dr. Goldenberg’s individual performance and the Company’s overall
performance. Dr. Goldenberg’s Annual Bonus Target is 30% of Base Salary, with a potential Bonus ranging from 0 to 150% of the Annual Bonus Target, conditional upon his achievement of performance goals as the Compensation Committee may
establish and determine. The Compensation Committee will determine the amount of Dr. Goldenberg’s discretionary annual bonus, if any, as of the end of each fiscal year during the Term of this Agreement, and shall pay such Bonus as soon as
practicable after such determination, but in no event later than 2.5 months after the end of each fiscal year, subject to the termination provisions contained in Section 10 of this Agreement. 
  

 5 

 (c) Equity Compensation. Throughout the Term of this Agreement,
Dr. Goldenberg is eligible to receive awards pursuant to the Company’s 2006 Stock Incentive Plan or any successor equity compensation plan of the Company, in amounts as determined by the Compensation Committee. Awards granted to
Dr. Goldenberg, if any, will be subject to the provisions of the Company’s 2006 Stock Incentive Plan (including any amendments and/or successor equity plan(s) of the Company), as well as any separate option agreement, restricted stock
purchase agreement or stock award agreement between Dr. Goldenberg and the Company, which states the terms and conditions of each such award (e.g., exercise price, expiration date, vesting schedule or stock options, and any restricted period
and\or other restrictions such as performance objectives relating to stock awards). Nothing in this section shall impact or affect any equity compensation awards Dr. Goldenberg may have received at any earlier time during his Term of
Employment. 
 4.2. Additional Incentive Compensation. In recognition of Dr. Goldenberg’s past and future integral
involvement in and contribution to all aspects of Immunomedics’ scientific and creative activities, and in consideration for his agreement to forego his right set forth in the Amended Agreements to develop or dispose of Undeveloped Assets, the
Company shall make the following payments to Dr. Goldenberg as additional incentive compensation (“Additional Incentive Compensation”). 
 (a) The Additional Incentive Compensation payments to which Dr. Goldenberg is entitled include: 
 (i) Transactional Payments; Net Revenue Payments. With respect to any fiscal year during the Term of the Agreement in which Immunomedics records an annual net loss (determined by Immunomedics in a manner consistent with generally
accepted accounting principles (“GAAP”) for the entire fiscal year as audited by Immunomedics’ independent registered public 

  

 6 

 
accounting firm), Immunomedics will pay to Dr. Goldenberg a sum equal to three quarters of one percent (.75%) of the total Consideration the Company
receives from any third party transaction, excluding third party financing transactions and any Disposition of Undeveloped Assets. With respect to any fiscal year during the Term of the Agreement in which Immunomedics records positive net income
(determined by Immunomedics in a manner consistent with GAAP) for the entire fiscal year as audited by Immunomedics’ independent registered public accounting firm, Immunomedics will pay to Dr. Goldenberg a sum equal to one and one-half
percent (1.5%) of Immunomedics’ Annual Net Revenue (as defined in Section 4.2(d)) for each such fiscal year (unless Dr. Goldenberg’s employment terminates pursuant to Sections 10(a) or 10(e)), and thereafter throughout the
non-competition period (as defined in Section 9(b)); and 
 (ii) Patent Lifetime Royalty Payments. Immunomedics
will pay to Dr. Goldenberg for each full fiscal year of the Company, a sum equal to a percentage of the annual Product Royalties the Company receives each such fiscal year on each of the products for which Dr. Goldenberg is an Inventor,
and all products using, related to or derived from products for which Dr. Goldenberg is an Inventor (“Patented Products”), which payments shall continue for each Patented Product for the remaining Life of the Patent covering each
Patented Product (collectively “Patent Lifetime Royalty Payments”). The percentage of Product Royalties that Immunomedics will pay to Dr. Goldenberg on each Patented Product will be determined based on the percentage of Product
Royalties that Immunomedics must pay to external third parties (any party other than a wholly owned subsidiary of Immunomedics) on each Patented Product, as follows: 
 (A) One percent (1%) of annual Product Royalties on Patented Products for which the Company pays a Royalty of more than 9.0 %
to external third parties; 
  

 7 

 (B) One and one-half percent (1.5%) of annual Product Royalties on Patented
Products for which the Company pays a Royalty of more than 6.0 % through 9.0 % to external third parties; 
 (C)
Two percent (2%) of annual Product Royalties on Patented Products for which the Company pays a Royalty of 6.0 % or less to external third parties. 
 Patent Lifetime Royalty Payments under Section 4.2(a)(ii) shall be due and owing from Immunomedics to Dr. Goldenberg (or his
estate or designated beneficiaries) throughout the Life of each Patent both during his employment with the Company and after his employment terminates, except that Lifetime Royalty Payments shall not be payable in the event an arbitrator or court
finds that Dr. Goldenberg committed a material breach of his covenants contained in Section 9. During the Term of Dr. Goldenberg’s employment with Immunomedics only, any quarterly payment of Patent Lifetime Royalty Payments
calculated under this Section 4.2(a)(ii) will be paid to Dr. Goldenberg (or his estate or designated beneficiaries) only to the extent that such Patent Lifetime Royalty Payments exceed the quarterly Minimum Payment paid to him pursuant to
Section 4.2(c). 
 (b) Payments Upon Disposition of Undeveloped Assets. In the event the Company, with its
Board’s approval, completes a Disposition during the Term of Employment, or within three (3) years thereafter, of any one or more of Immunomedics’ Undeveloped Assets for which Dr. Goldenberg was an Inventor, Immunomedics will pay
Dr. Goldenberg a sum equal to at least twenty percent (20%), or more (as determined by the Board), of the Consideration Immunomedics receives from each Disposition, upon receipt; provided, however that no such payment shall be due in the event
an arbitrator or court finds that Dr. Goldenberg committed a material breach of his covenants contained in Section 9. Subject to the preceeding conditions, the Company’s obligation to compensate Dr. Goldenberg under this provision, if
any, applies to all Dispositions completed within the Term of Employment or within three (3) years thereafter, even if the Company actually receives the Consideration at some time after the three (3) year period elapses. 
  

 8 

 (c) Minimum Payment. Immunomedics agrees to make a minimum payment of One Hundred
Fifty Thousand Dollars ($150,000) to Dr. Goldenberg during each of Immunomedics’ fiscal years during the Term of this Agreement, payable in equal quarterly payments, as an advance against the amounts due to Dr. Goldenberg pursuant to
Section 4.2(a) and (b) above. This minimum payment shall be prorated for any partial fiscal year of Immunomedics or partial year of service of Dr. Goldenberg covered by this Section 4.2. 
 (d) Definitions. As used in this Agreement, the following terms shall have the following meanings: 
 (i) “Annual Net Revenue” means Immunomedics’ total revenue determined for the fiscal year as determined by GAAP less
(i) Consideration received upon Disposition of Undeveloped Assets, (ii) Product Royalties on Patented Products (as defined in Section 4.2(a)(ii)) and (iii) amounts recorded as revenue by Immunomedics during such fiscal year that
are related to payments previously paid to Dr. Goldenberg under Section 4.2(a)(i) in any prior period. Further, Annual Net Revenue shall not include (A) net sales of any Acquired Asset, (B) any amounts received as cost
reimbursement payments, and (C) any revenue generated from interest or investment income of the Company. 
 (ii)
“Acquired Asset” means any product, technology or business to which Immunomedics acquired the rights from any third party (other than a wholly-owned subsidiary of Immunomedics), or affiliated group of such third parties, for an
aggregate consideration in excess of Five Million Dollars ($5,000,000), provided that Immunomedics did not materially contribute to the 

  

 9 

 
invention or development of such asset prior to such acquisition. For purposes of this definition, Immunomedics will be deemed to have materially contributed
to any product, technology or business which is covered by any Immunomedics’ patent. 
 (iii)
“Consideration” means cash, asset(s) or property, tangible or intangible, which Immunomedics receives directly or indirectly, for a Disposition (the transfer of relevant assets), including but not limited to sales proceeds, license
fees and licensing milestones, other milestone payments, up-front fees and sales bonuses. Consideration shall not include: (A) any consideration for or with respect to any Acquired Asset, (B) amounts paid to Immunomedics which clearly are
intended to constitute reimbursement of direct out-of-pocket costs incurred by Immunomedics for research, development or preclinical or clinical trials of the product or products which are the subject of the Disposition, regardless of whether paid
directly or indirectly, and however labeled, provided such amounts are paid pursuant to an agreement in effect at the time of such payment(s) and (C) any Patent Lifetime Royalty Payments (as defined in Section 4.2(a)(ii)). In calculating
the value of Consideration received in a Disposition, Immunomedics will offset the value of any thing of value that it had to grant or provide to the other party in exchange for the Disposition as an express element of the transaction. The parties
agree that any dispute with respect to the value of Consideration received in connection with any Disposition or any other dispute arising under this definition shall be submitted to arbitration pursuant to Section 8. 
 (iv) “Disposition” means any transfer, by way of sale, license or otherwise, to an unaffiliated third party, of any of
Immunomedics’ right, title or interest in or to any one or more of its products, technologies, intellectual property, businesses or other assets. Disposition includes any arrangements, whereby, Immunomedics combines with another entity and
forms a new entity in which Immunomedics holds any ownership interest and to which Immunomedics transfers, by way of sale, 

  

 10 

 
license or otherwise, any of Immunomedics’ right, title or interest in or to any one or more of its products, technologies, intellectual property, or
businesses. “Disposition” shall not include a transfer of all or substantially all of the assets or stock of Immunomedics pursuant to a Change in Control (as defined in Section 10(f)) or similar corporate transaction of Immunomedics
or to which it is a party. 
 (v) “Inventor” means a person(s) identified as an inventor of a patented
product, formula or idea on the disclosures initially filed in the relevant patent office(s) for such patent. 
 (vi)
“Life of a Patent” means the period beginning the first date on which a patent application is filed in any patent office covering any territory in the world and continuing as long as at least one (1) valid claim of the patent
exists in any territory in the world. It is understood that for purposes of this definition, the patent office in which the patent initially is filed is not likely to be located in or covering the same territory in which the last valid patent claim
remains, and that the Life of the Patent will cover all time periods between these two events. 
 (vii) “Product
Royalties” means all Consideration designated as a royalty, which Immunomedics receives for the license or use of its technology(ies), products, inventions, patents, or other intellectual property. For purposes of this Agreement, a patent
or copyright will be deemed valid in any territory in the world if at least one (1) valid claim of the patent or copyright exists in any territory in the world. 
 (viii) “Immunomedics” means Immunomedics and all of its direct and indirect subsidiaries or affiliates, including but not
limited to IBC. 
 (ix) “Undeveloped Assets” means any technology, product, agent, intellectual property,
business or other asset(s) or product(s) for which, at the time of Disposition, the Board of Directors of Immunomedics and Dr. Goldenberg have mutually determined that Immunomedics (A) is not currently budgeting for development,
(B) has not set a time table for 

  

 11 

 
development, at a level consistent with the financial support or timetable given to any other major project or technology for which the Company currently is
budgeting for either preclinical or clinical development, (C) has not funded with substantial research and development resources, or (D) has not entered Immunomedics’ sponsored Phase I or Phase II clinical trials. 
 (x) “Code” means the Internal Revenue Code of 1986, as amended. 
 (e) In Lieu of Other Payments. The Additional Incentive Compensation discussed in Sections 4.2(a)(i) and 4.2(a)(ii) of this
Agreement shall be in lieu of all other royalties and percentage payments to which Dr. Goldenberg otherwise previously might have been entitled relative to Undeveloped Assets under the Amended Agreements or otherwise, including but not limited
to payments pursuant to the License Agreement or on any other prior agreement between the parties. 
 (f) Reports and Payments. Within forty-five (45) days after the last day of each of its fiscal quarters (other than the final quarter of each fiscal year), Immunomedics will provide Dr. Goldenberg
with a written report that includes a preliminary computation (based upon unaudited financials) of Net Revenue, of Product Royalties, and of royalties on Patented Products (computed for such quarter in the same manner as Annual Net Revenue or annual
Product Royalties is to be computed for a fiscal year) and Disposition Payments (if any), and all amounts due to Dr. Goldenberg pursuant to Sections 4.2(a)(i), 4.2(a)(ii), and 4.2(b) with respect to such fiscal quarter. Within two and one half
(2  1/2) months after the last day of each of its fiscal years, Immunomedics will provide Dr. Goldenberg with a report that
includes computation of Annual Net Revenue, of annual Product Royalties, of annual royalties on Patented Products, and Disposition Payments (if any) for the entire year and all amounts due with respect to that year (based on audited financials), as
adjusted for the minimum payment provided to Dr. Goldenberg pursuant to Section 4.2(b) above. 
  

 12 

 Immunomedics will pay or transfer to
Dr. Goldenberg, within two and one half (2  1/2) months after the last day of each of its fiscal years, all amounts due
pursuant to Sections 4.2(a)(i) and 4.2 (a)(ii) with respect to that year. Immunomedics will pay or transfer to Dr. Goldenberg any participation in Consideration to which he is entitled pursuant to Section 4.2(b) above within fifteen
(15) calendar days following receipt of such Consideration by Immunomedics, regardless of how the Company may record the receipt of such Consideration for other accounting purposes. Immunomedics will provide such documentation as
Dr. Goldenberg deems reasonably necessary to verify the Company’s calculations of the payments due to Dr. Goldenberg pursuant to Sections 4.2(a)(i), 4.2(a)(ii), and 4.2(b). At least once during each fiscal year, Dr. Goldenberg
shall have the right to obtain access to Immunomedics sales and accounting books and records, and other documents Dr. Goldenberg deems reasonably necessary to confirm Immunomedics’ compliance with its obligations under this Agreement.

 5. Vacation and Fringe Benefits. 
 (a) Vacation. Dr. Goldenberg shall be entitled to a total of six (6) weeks paid vacation during each Contract Year
throughout the Term of this Agreement. Vacation benefits are subject to all other terms and conditions of Immunomedics’ standard vacation policies including but not limited to those relating to accrual of vacation time. 
 (b) Expenses. It is understood that Dr. Goldenberg will incur reasonable and necessary expenses in connection with his
employment and Immunomedics will reimburse Dr. Goldenberg for any such expenses in accordance with policies and limits as adopted by the Board. 
 (c) Employee Benefit Plans. In addition to the benefits expressly mentioned in this Agreement, Dr. Goldenberg shall receive all of the employment-related benefits established by the Board for executive
officers and such additional benefits as the Board may award to him from time to 

  

 13 

 
time. For purposes of this Agreement, employment-related benefits shall include, without limitation, participation in all employee welfare benefit plans and
employee pension benefit plans (as those terms are defined in the Employee Retirement Income Security Act of 1974, as amended), which Immunomedics may maintain from time to time during the Term of Employment. 
 6. Research Contracts or Grants. During the Term of this Agreement, Dr. Goldenberg occasionally may apply for research contracts for which he
would be named as principal research scientist or investigator. In such event, Dr. Goldenberg shall: 
 (a) Deliver
copies of such applications to Immunomedics prior to submission to the grantor or other contract entity. 
 (b) Make such
changes to application as Immunomedics may reasonably request. 
 (c) Submit such application naming Immunomedics as grantee
or contract beneficiary. 
 (d) Allow a mutually acceptable representative of Immunomedics to be present and participate in
all negotiations related to the proposed contract. All such contracts shall be subject to any internal approval process the Board may establish. 
 The provisions of this Section 6 shall not be applicable with respect to any research contracts for which Dr. Goldenberg may apply on behalf of the Center. 
 7. Prior Inventions and Discoveries. 
 (a) Discoveries. In exchange for Immunomedics’ agreement to provide the Additional Incentive Compensation detailed in Sections 4.2(a)(i), 4.2(a)(ii) and 4.2(b) of this Agreement, Dr. Goldenberg agrees
to forego any right to any additional compensation or consideration he otherwise would have the right to receive based on any ownership or interest he has in any and all 

  

 14 

 
ideas, inventions, improvements, discoveries, developments, products, compounds, compositions, apparatus, methods, formulae, processes, applications or uses
that he made or conceived (solely or jointly with another or others or by material contribution thereto in the course of his significant involvement in the direction of Immunomedics’ research and technology programs) during the Term of
Employment (collectively “Discoveries”). Dr. Goldenberg acknowledges that any interest he has or had in such Discoveries shall be the sole and exclusive property of Immunomedics, subject to any other applicable provisions of this
Agreement or any other agreements between the parties. 
 (i) Notwithstanding this provision, Immunomedics acknowledges that
it does not have any interest in any Discoveries that Dr. Goldenberg made/makes or conceived/conceives (solely or jointly with another or others or by material contribution thereto in the course of any significant involvement in the direction
of the Center’s research and technology programs) related to research performed by or for the Center in the course of his duties for the Center (“Center Discoveries”), and with respect to which Dr. Goldenberg has no individual
retained interest other than a royalty interest, and regardless of whether Immunomedics also may have an interest in the subject of such research. Dr. Goldenberg shall retain any royalty interest he may have in any Center Discoveries.
Immunomedics’ ownership rights in and to any Discovery made or conceived by Dr. Goldenberg (solely or jointly with another or others or by material contribution thereto) in the course of any significant involvement by Dr. Goldenberg
in the research or other activities of IBC, shall be only as may be expressly provided in any license, proprietary rights or other equivalent existing or future agreement that may exist between Immunomedics and IBC. 
 (ii) Notwithstanding this provision (Section 7(a)), Immunomedics further acknowledges that it does not have any interest in any
Discoveries (patented or unpatented) that Dr. Goldenberg made/makes or conceived/conceives (solely or jointly with another or others or by 

  

 15 

 
material contribution thereto), which are related to research performed by Dr. Goldenberg independent of his duties and responsibilities for
Immunomedics or the Center, provided that such Discoveries do not involve or relate to any technologies, research, or products being produced or developed by Immunomedics or by the Center, and provided that neither Immunomedics nor the Center made
any material contribution to such Discoveries. 
 (b) Disclosures. Dr. Goldenberg acknowledges and agrees that he
has provided Immunomedics with relevant information regarding all Discoveries covered under this Agreement. Dr. Goldenberg further agrees to provide Immunomedics with relevant information regarding any new Discoveries he might make at any time
during the Term of this Agreement and to comply with his fiduciary duties to Immunomedics. 
 (c) Cooperation of
Dr. Goldenberg. Both during and following the Term of Employment, upon the request of Immunomedics, Dr. Goldenberg shall execute and deliver any documents and give all reasonable assistance which may be essential or desirable to secure
to, assign and vest in Immunomedics the sole and exclusive right, title and interest in and to all Discoveries and other intellectual property. Such reasonable assistance may include but not be limited to the execution and delivery of patent
applications, assignments, affidavits, priority claims and other documents that Immunomedics, in its sole discretion, may determine are essential or desirable to obtain, maintain and/or defend such patents and to secure to and vest all appropriate
rights in Immunomedics. In addition, Dr. Goldenberg agrees that during and following the Term of Employment, at the request of Immunomedics, he generally will cooperate, appear and give evidence in any meetings or proceedings which may arise in
connection with Immunomedics’ efforts to secure, assign and vest for the Company the sole and exclusive right, title and interest in and to all Discoveries and other intellectual property. Immunomedics agrees to reimburse Dr. Goldenberg
for all reasonable expenses he incurs in providing 

  

 16 

 
such cooperation to Immunomedics. For purposes of this section, reasonable expenses may include but not be limited to travel costs, out of pocket expenses,
and any loss of salary or wages from another employer (if Dr. Goldenberg no longer is employed by Immunomedics). Any legal proceedings in connection with such matter shall be conducted by attorneys chosen and paid by Immunomedics.
Correspondingly, Immunomedics will provide all reciprocal support and reasonable assistance to Dr. Goldenberg that he may require to perfect his interest in any patent or Discovery, consistent with the terms of this Agreement. 
 (d) Dispute Resolution. In the event that a dispute should arise regarding whether any Discoveries are the property of
Immunomedics, or belong to the Center, if the relevant parties are not able to reach agreement, they shall submit the dispute to final and binding arbitration pursuant to Section 8 of this Agreement. 
 8. Arbitration. All disputes arising under this Agreement, other than actions to enforce the restrictions detailed in Section 9, or as
otherwise expressly stated in this Agreement, shall be subject to final and binding arbitration between the parties. Such arbitration shall be submitted to a single arbitrator selected by mutual agreement of the parties, and shall be conducted at a
mutually agreeable site located within a ten (10) mile radius of Immunomedics’ principal office in Morris Plains, New Jersey. All arbitration proceedings shall be conducted pursuant to the American Arbitration Association Rules for
Employment Disputes. 
 9. Restrictive Covenants. 
 (a) Confidentiality. Dr. Goldenberg agrees that his services to Immunomedics were and are of a special, unique and
extraordinary character, and that his position places him in a position of confidence and trust with Immunomedics’ customers and employees. Dr. Goldenberg also recognizes that his position with Immunomedics gives him substantial access to
Confidential 

  

 17 

 
Information (as defined below), the disclosure of which to competitors of Immunomedics would cause Immunomedics to suffer substantial and irreparable damage.
Therefore, Dr. Goldenberg recognizes that it is in Immunomedics’ legitimate business interest to restrict Dr. Goldenberg’s use of Confidential Information for any purposes other than the discharge of his employment duties at
Immunomedics, and to limit any potential appropriation of Confidential Information by Dr. Goldenberg for the benefit of Immunomedics’ competitors and to the detriment of Immunomedics. Accordingly, Dr. Goldenberg agrees as follows:

 (i) Throughout the Term of this Agreement and at all times thereafter, Dr. Goldenberg will not at any time reveal to
any person or entity any of the trade secrets or confidential information of Immunomedics, or of any third party, which Immunomedics is under an obligation to keep confidential (including but not limited to trade secrets and non-public information
regarding inventions, products, designs, methods, know-how, techniques, systems, processes, software programs, works of authorship, customer lists, projects, intellectual property, plans and proposals) (“Confidential Information”), except
as may be required in the ordinary course of performing Dr. Goldenberg’s duties as an employee of Immunomedics or for the benefit of Immunomedics, with the Company’s knowledge and consent. Dr. Goldenberg will keep secret all
matters entrusted to him and not use or attempt to use any Confidential Information in any manner which may injure or cause direct or indirect loss to Immunomedics. 
 (ii) Confidential Information shall not include (and the above restrictions shall not apply to): (A) information that at the time of
disclosure is in the public domain through no fault of Dr. Goldenberg; (B) information Dr. Goldenberg receives from a third party outside of Immunomedics that was disclosed without a breach of any confidentiality obligation;
(C) information approved for release by written authorization of Immunomedics; or (D) information that may be 

  

 18 

 
required by law or an order of any court, agency or proceeding to be disclosed. In the event that Dr. Goldenberg is requested or required by law or an
order of any court, agency or proceeding to disclose Confidential Information, Dr. Goldenberg will provide Immunomedics with prompt notice of such request so that Immunomedics may timely seek an appropriate protective order or waive
Dr. Goldenberg’s confidentiality obligations under this Agreement. Dr. Goldenberg will provide reasonable assistance to Immunomedics in the event the Company notifies him that it intends to seek to obtain an appropriate protective
order. If Dr. Goldenberg gives such notice to Immunomedics, but does not receive timely notice of either a protective order or a waiver from the Company and, in the written or oral opinion of his legal counsel (the reasonable fee for which
opinion shall be paid or reimbursed by Immunomedics), Dr. Goldenberg is compelled to disclose Confidential Information or face liability for contempt or other censure or penalty, then Dr. Goldenberg may disclose such Confidential
Information to the extent so required, without violating this provision or incurring any liability under the Agreement. 
 (iii) Return of Company Property. Dr. Goldenberg agrees that upon the termination of his employment with Immunomedics, regardless of the timing or reason for termination, he will not take or retain, without written
authorization, any documents, files or other property of Immunomedics. Except as provided in this Agreement, Dr. Goldenberg will return promptly to Immunomedics any such documents, files or property in his possession or custody, including any
copies thereof maintained in any medium or format. Dr. Goldenberg recognizes that all documents, files and property containing Confidential Information which he has received and will receive from Immunomedics, including but not limited to
scientific research, customer lists, handbooks, memoranda, product specifications, and other materials are for the exclusive use of Immunomedics and its employees while working on behalf of Immunomedics, and that Dr. Goldenberg has no claim or
right to the continued use, possession or custody of such documents, files or property following the termination of his employment. 
  

 19 

 Notwithstanding this provision, Immunomedics acknowledges and agrees that
Dr. Goldenberg may retain all working documents that he determines he may need with regard to any patent(s) he is preparing for filing, pursuing, or prosecuting on behalf of Immunomedics. Immunomedics further acknowledges and agrees that any
materials created prior to Dr. Goldenberg’s employment by Immunomedics, and any materials created in connection with his employment with the Center or IBC (“Non-proprietary Materials”) are not the property of Immunomedics, and
all materials that are generally available to the public and/or in the public domain (“Public Materials”), are not the exclusive property of Immunomedics. Immunomedics further agrees that Dr. Goldenberg may retain possession of all
Non-Proprietary Materials and may retain copies of all Public Materials, at all times following the end of his employment. 
 (b) Non-Competition. Throughout the Term of Employment and for a period of three (3) years thereafter, Dr. Goldenberg will not, without the prior written approval of the Board, whether alone or as a partner, officer,
director, consultant, agent, employee or stockholder of any company or other commercial enterprise, directly or indirectly engage in any business or other activity in the United States or Canada which competes with Immunomedics. The foregoing
prohibition shall not prevent Dr. Goldenberg’s employment or engagement following his Term of Employment, with any company or business organization, as long as the activities of any such employment or engagement, in any capacity, do not
involve work on matters related to the products being researched, developed, manufactured, or marketed by Immunomedics during the Term of Employment. Dr. Goldenberg shall be permitted to own securities of a public company not in excess of five
percent (5%) of any class of such securities and to own stock, partnership interests or other securities of any entity 

  

 20 

 
not in excess of five percent (5%) of any class of such securities, and to own any amount of interest in the Center, Immunomedics, and/or in IBC (or a
subsidiary or affiliate of same), and such ownership taken alone shall not be considered to be in competition with Immunomedics or a violation of this Agreement. 
 (c) Non-Solicitation. Throughout the Term of Employment and for a period of three (3) years thereafter, Dr. Goldenberg
agrees that he will not: 
 (i) directly or indirectly solicit, entice or induce any Immunomedics’ customer to become a
customer of any other person, firm or corporation with respect to products then sold or under development by Immunomedics, or to cease doing business with Immunomedics, and Dr. Goldenberg shall not approach any such person, firm or corporation
for such purpose or authorize or knowingly approve the taking of such actions by any other person; or 
 (ii) directly or
indirectly solicit or recruit any employee of Immunomedics to work for a third party other than Immunomedics (excluding the Center and excluding newspaper or similar print or electronic solicitations of general circulation); provided, however, that
the otherwise applicable non-solicitation period shall not be reduced in the event of Dr. Goldenberg’s termination for Cause or the cessation of Severance Payments as a result of Dr. Goldenberg’s violation of his obligations
under this Section 9. 
 (d) Enforcement. 
 (i) Dr. Goldenberg acknowledges and agrees that the type and periods of restrictions imposed in this Section 9 of this Agreement
are fair and reasonable, and that such restrictions are intended solely to protect the legitimate interests of Immunomedics, rather than to prevent Dr. Goldenberg from earning a livelihood. Dr. Goldenberg recognizes that Immunomedics
competes worldwide, and that his access to Confidential Information makes it necessary for Immunomedics to restrict his post-employment activities in any market in which Immunomedics competes, and in which his access to Confidential Information and
other proprietary information could be used to the detriment of Immunomedics. 
  

 21 

 (ii) Injunctive Relief. Dr. Goldenberg acknowledges and agrees that if he
breaches any of the covenants, restrictions and agreements contained in this Section 9, Immunomedics will suffer irreparable loss and injury, and that damages arising out of such a breach may be difficult to ascertain. Therefore,
Dr. Goldenberg agrees that, in addition to all other remedies provided at law or at equity, Immunomedics shall be entitled to have the covenants, restrictions and agreements contained in this Section 9 specifically enforced (including,
without limitation, by temporary, preliminary, and permanent injunctions and restraining orders) by any state or federal court in the State of New Jersey having equity jurisdiction and Dr. Goldenberg agrees to be subject to the jurisdiction of
such court. 
 (iii) Monetary Relief. In addition to its right to seek an injunction, in the event Dr. Goldenberg
breaches any provision of this Section 9, Immunomedics also shall have the right to pursue monetary damages against Dr. Goldenberg for such breach. 
 (iv) If either party fails to take action to remedy any breach of this Agreement or any portion of this Agreement by the other party, such
inaction shall not operate or be construed as a waiver of any subsequent breach by either party of the same or any other provision, agreement or covenant. 
 (v) Dr. Goldenberg acknowledges and agrees that the payments and benefits to be provided to him under this Agreement are provided, in part, as consideration for the covenants in this Section 9. 

 

 22 

 (vi) In the event that any court of competent jurisdiction or any arbitration determines
that any restriction contained in this Agreement is overly broad with respect to scope, time or geographical coverage, the parties agree that such restriction(s) may be modified and narrowed, either by a court, arbitrator, or by Immunomedics only to
the extent necessary to make this provision enforceable, and that such determination will not affect the enforceability of any other provision of this Agreement. 
 (e) Exclusions Relating to the Center. Immunomedics and Dr. Goldenberg agree that any work that Dr. Goldenberg performs
for or on behalf of the Center and/or any of its affiliates, and any documents or other confidential information or materials developed, assembled, or received while performing such work, are not subject to the provisions of this Section 9, and
that any such work will not constitute a violation of the terms of this Agreement. 
 10. Termination. Notwithstanding the provisions
of Section 2 above, the employment of Dr. Goldenberg shall terminate upon the happening of any of the following events: 
 (a) The death of Dr. Goldenberg. 
 (b) Immunomedics and Dr. Goldenberg mutually agree to terminate this
Agreement. 
 (c) At Immunomedics’ option, if Dr. Goldenberg suffers a Permanent Disability. For purposes of this
Agreement, Dr. Goldenberg shall be deemed to have incurred a “Permanent Disability” if, by reason of his physical or mental medical condition, as determined by a physician jointly designated by Immunomedics and Dr. Goldenberg, he
is unable to perform his duties under this Agreement for a period of (i) 180 consecutive days, or (ii) 245 days in any 365 consecutive days period. Dr. Goldenberg will not be deemed Permanently Disabled if he submits a written opinion
by a physician designated by or reasonably satisfactory to Immunomedics stating that Dr. Goldenberg will be able to resume continuous full-time performance of his obligations under this Agreement within 365 days following the commencement of
such disability and Dr. Goldenberg actually returns to full-time work within the same 365 day period. In the event Dr. Goldenberg and Immunomedics cannot agree 

  

 23 

 
upon a physician to determine whether Dr. Goldenberg is suffering a Permanent Disability, they each may select a physician and the two physicians so
selected will jointly select a third physician, who will examine Dr. Goldenberg to determine whether he is suffering a Permanent Disability, and will provide a written report of his/her conclusions all parties. 
 (d) By Dr. Goldenberg, for Good Reason. For purposes of this Agreement, Good Reason is defined as occurrence of any of the following
events or conditions, unless Dr. Goldenberg has expressly consented in writing thereto, or except as a result of Dr. Goldenberg’s physical or mental incapacity or as described in the last sentence of this subsection (d): 

(i) A material reduction in Dr. Goldenberg’s Base Salary; 
 (ii) The material diminution of the Dr. Goldenberg’s duties, responsibilities, powers or authorities, including the assignment
of any duties and responsibilities inconsistent with his position as Chief Scientific Officer and Chief Medical Officer of Immunomedics; or 
 (iii) Immunomedics requires that Dr. Goldenberg’s principal office location be moved to a location more than 50 miles from his principal office location immediately before the change. 
 Notwithstanding the foregoing, Dr. Goldenberg shall not have Good Reason for termination unless he gives written notice of termination for Good Reason within 15
days after the event giving rise to Good Reason occurs and Immunomedics does not correct the action or failure to act that constitutes the grounds for Good Reason, as set forth in Dr. Goldenberg’s notice of termination, within 30 days
after the date on which he gives written notice of termination. 
  

 24 

 (e) By the Company, for “Good Cause,” which means: 
 (i) Dr. Goldenberg commits continued, knowing and intentional neglect, substantial nonperformance or a demonstrated continuing
inability to perform his obligations under this Agreement (other than due to physical or mental disability) and Immunomedics provides him with written notice of such deficiencies and ninety (90) days to correct such deficiencies; or 

(ii) An arbitrator or a court finds that Dr. Goldenberg committed an act of fraud or dishonesty related to the performance of
duties under this Agreement; or 
 (iii) Dr. Goldenberg commits any material breach of any of the provisions of this
Agreement other than those covered under Sections 10(e)(i) or 10(e)(ii), and fails to cure such breach within ninety (90) days after receiving written notice from Immunomedics of such breach. 
 (f) By Dr. Goldenberg upon ninety (90) days prior written notice to Immunomedics or its successor, to be effective not later
than the second anniversary of a Change in Control of Immunomedics. For purposes of this Agreement, a Change of Control of Immunomedics is defined as: 
 (i) A merger, consolidation or reorganization approved by the Company’s stockholders, unless securities representing more than fifty percent (50%) of the total and combined voting power of the outstanding
voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly, by the persons who beneficially owned the Company’s outstanding voting securities immediately prior to such transaction; or

 (ii) The sale, transfer or other disposition of all or substantially all of the Company’s assets as an entirety or
substantially as an entirety, occurring within a 12-month period, and representing, at a minimum, not less than 40 percent of the total gross fair market value of all assets of the Company, to any person, entity, or group of persons acting in
consort, other than a sale, transfer or disposition to: (A) a shareholder of the Company in exchange for or with respect to its 

  

 25 

 
stock; (B) an entity, 50 percent or more of the total value or voting power of which is owned, directly or indirectly, by the Company; (C) a
person, or more than one person acting as a group, that owns, directly or indirectly, 50 percent or more of the total value or voting power of the outstanding stock of the Company; or (D) an entity, at least 50 percent of the total value or
voting power of which is owned by a person described in (C); or 
 (iii) Any transaction or series of related transactions
pursuant to which any person or any group of persons comprising a “group” within the meaning of Rule 13d-5(b)(1) under the Securities Exchange Act of 1934, as amended (other than the Company or a person that, prior to such transaction or
series of related transactions, directly or indirectly controls, is controlled by or is under common control with, the Company) becomes directly or indirectly the beneficial owner (within the meaning of Rule 13d-3 of the Securities Exchange Act of
1934, as amended) of securities possessing (or convertible into or exercisable for securities possessing) more than fifty percent (50%) of the total combined voting power of the Company’s securities outstanding immediately after the
consummation of such transaction or series of related transactions, whether such transaction involves a direct issuance from the Company or the acquisition of outstanding securities held by one or more of the Company’s stockholders; or

 (iv) A change in the composition of the Board over a period of twelve (12) consecutive months or less such that a
majority of the Board members ceases by reason of one or more contested elections for Board membership to be comprised of individuals whose election is endorsed by a majority of the members of the Board immediately before the date of election.

  

 26 

 A transaction shall not constitute a Change of Control if its sole purpose is to change the state of the Company’s
incorporation or to create a holding company that will be owned in the same proportions by the persons who held the Company’s securities immediately before such transaction. 
 (g) Except as provided in Sections 10(a), 10(c) or 10(e)(ii), with respect to death, Permanent Disability and fraud/dishonesty,
respectively, termination by either party hereunder shall be effective upon the effective date of notice of such termination by the terminating party to the other party specifying the reasons, if any, for such termination. 
 (h) The foregoing provisions of this Section 10 notwithstanding, Dr. Goldenberg will not be deemed to have had a termination of
employment prior to the date as of which Immunomedics and Dr. Goldenberg reasonably anticipate that the level of future services to be provided by Dr. Goldenberg to Immunomedics, whether as an employee or an independent contractor, will
permanently decrease to a level which is less than fifty (50) percent of the average level of services provided over the immediately preceding thirty-six (36) months. 
 11. Decisions and Determinations of the Board. Neither Dr. Goldenberg nor any of his affiliates shall participate in any decision by the
Board, or any Board committee, which affects any of his rights or obligations under this Agreement. Except as otherwise expressly provided in this Agreement, all actions of the Board provided for in this Agreement, including but not limited to
determinations, consents and approvals, shall be in the Board’s sole and uncontrolled discretion. 
 12. Cooperation with
Immunomedics After Expiration or Termination. Following the end of the Term of Employment, regardless of timing or cause, Dr. Goldenberg will cooperate fully with Immunomedics in all matters relating to the winding up of work on behalf of
Immunomedics and the orderly transfer of any pending work to other employees of Immunomedics. Dr. Goldenberg agrees to be available and to provide services on a full-time or part-time basis, as Immunomedics may request, 

  

 27 

 
during the first thirty (30) calendar days following the end of his employment. In consideration for the Patent Lifetime Royalty Payments set out in
Section 4.2(a)(ii) of this Agreement, Dr. Goldenberg specifically agrees to provide to Immunomedics all assistance reasonably necessary to assist Immunomedics in defending and prosecuting any patents in force. This obligation will continue
for the life of the patent, provided Dr. Goldenberg is medically able to provide such assistance. Nothing herein shall limit Immunomedics’ obligation to pay, and Dr. Goldenberg’s or his estate’s right to receive, the
Additional Incentive Compensation, Patent Lifetime Royalty Payments and Disposition Payments under Sections 4.2(a)(ii) and 4.2(b) of this Agreement, for the specified periods or throughout the Life of the Patents, as the case may be. 
 13. Payment and Benefits on Termination or Expiration. 
 (a) Disability and Death. Immunomedics, with the full cooperation of Dr. Goldenberg, shall acquire and provide for life
insurance for Dr. Goldenberg as required under Section 5(d) and Exhibit A of this Agreement. Such insurance shall remain in full force and effect (i) for the Term of this Agreement and (ii) for three (3) years after the Term
of this Agreement, unless Dr. Goldenberg initiates early termination other than for Good Reason (as defined in Section 10(d) or 10(f)), or Immunomedics initiates early termination for Good Cause (as defined in Section 10(e)).

 (b) Guaranteed Payments. Not later than sixty (60) days following the termination of Dr. Goldenberg’s
employment, regardless of the reason or timing of the termination, Immunomedics will make payment to Dr. Goldenberg for all annual Base Salary, Bonus, Minimum Payments, and Additional Incentive Compensation earned through the date of
termination, any benefits accrued in accordance with the terms of any applicable benefit plans and programs of the Company (including but not limited to earned but unused vacation), and will continue all payments pursuant to Section 4.2(a)(ii)
and 4.2(b) for the time periods provided in those sections of this Agreement (collectively, “Guaranteed Payments”). There are no preconditions to Immunomedics’ obligation to pay, and to Dr. Goldenberg’s right to receive,
Guaranteed Payments under this Section 13(b) of this Agreement. 
  

 28 

 (c) Severance 
 (i) If Dr. Goldenberg’s employment terminates pursuant to Section 10(a) (death), in addition to receiving the Guaranteed
Payments, his estate will receive a Severance Payment equal to the amount of the Annual Target Bonus, if any, (pursuant to Section 4.1(b)) payable for the fiscal year in which the termination occurs (prorated to reflect
Dr. Goldenberg’s actual period of service during such fiscal year), such amount to be paid within sixty (60) days following the date of Dr. Goldenberg’s death. 
 (ii) If Dr. Goldenberg’s employment terminates by mutual agreement of the parties pursuant to Section 10(b) (mutual
agreement), 10(c) (permanent disability) or pursuant to expiration or non-renewal as set forth in Section 2, in addition to receiving the Guaranteed Payments, Dr. Goldenberg will receive payment for the Annual Target Bonus, if any,
(pursuant to Section 4.1(b)) payable for the fiscal year in which the termination occurs (prorated to reflect Dr. Goldenberg’s actual period of service during such fiscal year), such amount to be paid within sixty (60) days
following the date of termination of employment, and any other benefits or payments to which the parties may agree. 
 (iii)
If Dr. Goldenberg’s employment terminates for Good Cause pursuant to Section 10(e), the only post-termination payment or benefit he will receive is the Guaranteed Payments. 
 (iv) If Immunomedics terminates Dr. Goldenberg’s employment without Good Cause (as defined in Section 10(e), or if
Dr. Goldenberg terminates his employment for Good Reason pursuant to Section 10(d), in addition to the Guaranteed Payments, Immunomedics will pay Dr. Goldenberg Severance payments in an amount equal to his Total Annual Compensation
(as such 

  

 29 

 
exists as of the date of termination), paid or provided for the remaining balance of the Term of this Agreement on the same schedule as would apply if
Dr. Goldenberg remained an active employee of Immunomedics, plus an additional lump sum amount equal to two times (2x) his Total Annual Compensation (as such exists as of the date of termination), such lump sum to be paid within sixty
(60) days following the date of termination of Dr. Goldenberg’s employment. “Total Annual Compensation” shall include all cash payments due to Dr. Goldenberg for the applicable Contract Year as set out in
Sections 4.1(a) and (b), 4.2(a)(i), and 4.2(c), but shall not include payments provided pursuant to Sections 4.2(a)(ii) and 4.2(b) (which shall continue pursuant to the terms of those Sections). 
 (A) In the event Dr. Goldenberg’s employment terminates as provided in Section 13(c)(iv), for the balance of the Term of
this Agreement and for a period of two (2) years following the end of the Term of this Agreement (the “Severance Period”), the Company will, to the extent permitted under Section 409A of the Code, continue to provide to
Dr. Goldenberg all of the benefits of his employment, as if he remained employed, as set as in Sections 4.1(c), 5(b), 5(c) and 5(d). Immunomedics shall, during the Severance Period and for a period of eighteen (18) months thereafter, pay
Dr. Goldenberg each month an amount equal to the monthly COBRA medical insurance cost under Immunomedic’s medical plan for Dr. Goldenberg and any eligible dependent(s) (less any required employee payments calculated as if
Dr. Goldenberg had continued to be an employee), and all other employee benefits pursuant to Section 5(c) and all life insurance policies pursuant to Section 5(d) and Exhibit A. Throughout the Severance Period, Immunomedics also will
pay for the reasonable cost of an office and secretarial support for Dr. Goldenberg, and all reasonable expenses to set up and maintain such office (including telephone, fax and Internet access, office supplies and equipment, furniture, etc.),
at a reasonable location of Dr. Goldenberg’s choice. 
  

 30 

 (v) If Dr. Goldenberg terminates his employment following a Change in Control
pursuant to Section 10(f), in addition to the Guaranteed Payments, Immunomedics will pay Dr. Goldenberg, with sixty (60) days following the date of his termination of employment, a Severance payment in an amount equal to a lump sum
amount equal to three times (3x) his Total Annual Compensation, as previously defined above, (as such exists as of the date of termination). 
 (A) In the event Dr. Goldenberg’s employment terminates as provided in Section 13(c)(v), for the balance of the Term of this Agreement and for or a period of three (3) years following the end of
the Term of this Agreement (the “Enhanced Severance Period”), the Company or its successor, as the case may be, will continue to provide to Dr. Goldenberg all of the benefits of his employment, as if he remained employed, as set out
in Sections 4.1(c), 5(b), 5(c) and 5(d). Immunomedics shall, during the Enhanced Severance Period and for a period of eighteen (18) months thereafter, pay Dr. Goldenberg each month an amount equal to the monthly COBRA medical insurance
cost under Immnunomedics medical plan for Dr. Goldenberg and any eligible dependent(s) (less any required employee payments calculated as if Dr. Goldenberg had continued to be an employee), and all other employee benefits pursuant to
Section 5(c) and all life insurance policies pursuant to Section 5(d) and Exhibit A. Throughout the Enhanced Severance Period, Immunomedics also will pay for the reasonable cost of an office and secretarial support for Dr. Goldenberg,
and all reasonable expenses to set up and maintain such office (including telephone, fax and Internet access, office supplies and equipment, furniture, etc.), at a reasonable location of Dr. Goldenberg’s choice. 
  

 31 

 (d) In the event Dr. Goldenberg should expire during either Severance Period,
Immunomedics will continue to make all Severance Cash Payments to his estate through the end of the Severance Period, continue to pay his estate a monthly amount for the cost of medical coverage for Dr. Goldenberg’s eligible dependents in
accordance with Sections 13(c)(iv)(A) or 13(c)(v)(A), as applicable, and will continue to pay all Patent Lifetime Royalty Payments under Section 4.2(a)(ii) for the Life of each Patent. 
 (e) Specific Issues in the Event of a Change in Control (regardless of whether Dr. Goldenberg terminates his employment): 

(i) Notwithstanding any provision to the contrary in the Company’s 2006 Stock Incentive Plan or any applicable plan, program or
agreement, upon the occurrence of a Change of Control, all stock options, restricted stock and other equity rights held by Dr. Goldenberg will become fully vested and/or exercisable, as the case may be, on the date on which the Change in
Control occurs, and all stock options held by Dr. Goldenberg shall remain exercisable, notwithstanding anything in any other agreement governing such options, for a period of twenty-four (24) months following the end of the remaining
balance of the Term of the Agreement; provided, however, that in no event will the option be exercisable (a) beyond its original term; or (b) beyond the extension period permitted under Section 409A of the Code. 
 (ii) Notwithstanding any provision to the contrary in any applicable plan, program or agreement providing for supplemental retirement
benefits or deferred compensation, upon the occurrence of a Change of Control, Dr. Goldenberg’s accrued benefit under such plans, programs or agreements shall become fully vested on the date on which the Change in Control occurs, and shall
be immediately payable on Dr. Goldenberg’s date of termination, unless Dr. Goldenberg has made a valid election under such plan, program or agreement to defer payment of such accrued benefits. 
  

 32 

 (iii) Increase in Payments Upon a Change of Control. 
 (A) Notwithstanding anything in this Agreement to the contrary, in the event that it shall be determined that any payment or distribution
by the Company to or for the benefit of Dr. Goldenberg, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (a “Payment”), would constitute an “excess parachute
payment” within the meaning of Section 280G of the Code, the Company shall pay to Dr. Goldenberg an additional amount (the “Gross-Up Payment”) such that the net amount retained by Dr. Goldenberg after deduction of any
excise tax imposed under Section 4999 of the Code, and any federal, state and local income tax, employment tax and excise tax imposed upon the Gross-Up Payment, shall be equal to the Payment. For purposes of determining the amount of the
Gross-Up Payment, unless Dr. Goldenberg specifies that other rates apply, Dr. Goldenberg shall be deemed to pay federal income tax and employment taxes at the highest marginal rate of federal income and employment taxation in the calendar
year in which the Gross-Up Payment is to be made and state and local income taxes at the highest marginal rate of taxation in the state and locality of Dr. Goldenberg’s residence on his termination date, net of the maximum reduction in
federal income taxes that may be obtained from the deduction of such state and local taxes. 
 (B) All determinations to be
made under this Section shall be made by the Company’s independent public accountant immediately prior to the Change of Control or by another independent public accounting firm mutually selected by the Company and Dr. Goldenberg before the
date of the Change of Control (the “Accounting Firm”), which firm shall provide its determinations and any supporting calculations both to the Company and Dr. Goldenberg within 20 days after Dr. Goldenberg’s termination date. Any
such determination by the Accounting Firm shall be binding upon the Company and Dr. Goldenberg. 
  

 33 

 (C) The Company shall pay the Gross-Up Payment as and when the related excise tax under
section 4999 of the Code (“Excise Tax”) is incurred. The Gross-Up Payment shall be paid in accordance with Section 409A of the Code, to the extent applicable. If required in order to comply with Section 409A of the Code,
(i) the Gross-Up Payment attributable to Payments other than severance compensation shall be paid in a lump sum payment upon the closing of the Change of Control, subject to Section 19(c) of this Agreement, if applicable, and (ii) the
Gross-Up Payment attributable to severance compensation shall be paid in a lump sum payment on the first day on which severance compensation is paid. If the amount of a Gross-Up Payment cannot be fully determined by the date on which the applicable
portion of the Payment becomes subject to the Excise Tax (“Payment Date”), the Company shall pay to Dr. Goldenberg by the Payment Date an estimate of such Gross-Up Payment, as determined by the Accounting Firm, and the Company shall
pay to Dr. Goldenberg the remainder of such Gross-Up Payment (if any) as soon as the amount can be determined, but in no event later than 20 days after the Payment Date. 
 (D) All of the fees and expenses of the Accounting Firm in performing the determinations referred to in this Section shall be borne
solely by the Company. The Company agrees to indemnify and hold harmless the Accounting Firm from any and all claims, damages and expenses resulting from or relating to its determinations pursuant to this Section, except for claims, damages or
expenses resulting from the gross negligence or willful misconduct of the Accounting Firm. 
  

 34 

 (f) Required Postponement for Specified Executives. 
 (i) If Dr. Goldenberg is considered a Specified Executive (as defined below) and payment of any amounts under this Agreement is
required to be delayed for a period of six months after separation from service pursuant to Section 409A of the Code, payment of such amounts shall be delayed as required by Section 409A, and the accumulated postponed amounts, with accrued
interest as described below, shall be paid in a lump sum payment within five days after the end of the six month period. If Dr. Goldenberg dies during the postponement period prior to the payment of benefits, the amounts postponed on account of
Section 409A, with accrued interest as described in subsection (b) below, shall be paid to the personal representative of Dr. Goldenberg’s estate within 60 days after the date of Dr. Goldenberg’s death. 
 (ii) If payment of any amounts under this Agreement is required to be delayed pursuant to section 409A of the Code, the Company shall pay
interest on the postponed payments from the date on which the amounts otherwise would have been paid to the date on which such amounts are paid at an annual rate equal to the rate published in the Wall Street Journal as the “prime rate” as
of Dr. Goldenberg’s date of termination. 
 (iii) The term “Specified Executive” means an employee who, at
any time during the 12-month period ending on the identification date (defined below), is (i) an officer of the Company or a member of its controlled group (as determined for purposes of section 416(i) of the Code) who has annual compensation
greater than $135,000 (or such other amount as may be in effect under Section 416(i)(1) of the Code), (ii) a 5% owner of the Company or (iii) a 1% owner of the Company who has annual compensation greater than $150,000. The
identification date shall be each December 31, and the determination of Specified Executives as of such identification date shall apply for the 12-month period following April 1 after the identification date. The determination of Specified
Executives, including the number and identity of persons considered officers, shall be made by the Company in accordance with the provisions of Sections 416(i) and 409A of the Code and the regulations issued thereunder. 
  

 35 

 (g) Required Release. As a condition to receiving any Severance Payments under
this Section (other than Guaranteed Payments, which are not subject this condition), Immunomedics may require Dr. Goldenberg to execute a written release of any and all claims against the Company and all related parties with respect to all
matters arising out of Dr. Goldenberg’s employment by the Company, or the termination thereof (the “Release”) in a form provided by the Company but acceptable to Dr. Goldenberg. The Company will not start making any
Severance payments under this Section (other than Guaranteed Payments) unless Dr. Goldenberg signs a written release and does not revoke his consent to the release within seven (7) days after submitting to the Company. 
 14. Legal Costs. Immunomedics shall reimburse to Dr. Goldenberg, or directly pay to Dr. Goldenberg’s attorneys, the reasonable fees
and disbursements incurred by him for the negotiation and preparation of this Agreement, up to Thirty-Five Thousand Dollars ($35,000). 
 15.
Parties in Interest. This Agreement is personal in nature and no party to this Agreement may assign or transfer this Agreement or any rights or obligations hereunder, without the first obtaining the express written consent of the other party.

 16. Notices. All notices, proposals, submissions, offers, approvals, agreements, elections, consents, acceptances, waivers,
reports, plans, requests, instructions, options or other exercise of rights, and other communications required or permitted to be made or given hereunder (all of the foregoing hereinafter collectively referred to as “communications”) shall
be in writing, signed by or on behalf of the notifying party, and shall be deemed to have been duly made or given when (i) delivered personally with receipt acknowledged, (ii) sent by registered or certified mail or equivalent, return
receipt 

  

 36 

 
requested, (iii) sent by facsimile or (iv) sent by recognized overnight courier for delivery within 48 hours, in each case addressed or sent to the
parties at the following addresses or facsimile numbers or to such other or additional address or facsimile number as any party shall hereafter specify by Communication to the other parties: 
  

			
	To:	  	Immunomedics, Inc.
		
		  	300 American Road
		
		  	Morris Plains, New Jersey 07950
		
		  	Attn: Chief Executive Officer
		
		  	and Corporate Secretary
		
		  	Fax #: (973) 605-8282
		
	with a copy to:	  	Andrew P. Gilbert, Esq.
		
		  	Morgan, Lewis & Bockius LLP
		
		  	502 Carnegie Center
		
		  	Princeton, New Jersey 08540-6241
		
		  	Fax #: (609) 919-6701
		
	To:	  	Dr. David M. Goldenberg
		
	with a copy to:	  	Douglas S. Zucker, Esq.
		
		  	Schenck, Price, Smith & King, LLP
		
		  	P.O. Box 905
		
		  	10 Washington Street
		
		  	Morristown, New Jersey 07963-0905
		
		  	Fax #: (973) 540-7300

  

 37 

 or to the appropriate attorney of record for Immunomedics or Dr. Goldenberg, respectively. Notice of change of
address shall be deemed given when actually received or upon refusal to accept delivery thereof; all other communications shall be deemed to have been given, received and dated on the earliest of: (1) when actually received or upon refusal to
accept delivery thereof, (ii) on the date when delivered personally, (iii) one (1) day after being sent by facsimile or telex, (iv) 48 hours after being sent by overnight courier and (v) three (3) business days after
mailing. 
 17. Governing Law. This Agreement and the rights of the parties hereunder shall be governed by and construed in accordance
with the laws of the state of New Jersey, without giving effect to the principles of conflict of laws. 
 (a)
Section 409A of the Code. This Agreement is intended to comply with Section 409A of the Code and its corresponding regulations, to the extent applicable. Notwithstanding anything in this Agreement to the contrary, payments may only
be made under this Agreement upon an event and in a manner permitted by Section 409A of the Code, to the extent applicable. For purposes of Section 409A of the Code, each payment under this Agreement shall be treated as a separate payment
and the right to a series of installment payments shall be treated as the right to a series of separate payments. All reimbursements provided under this Agreement shall be made or provided in 

  

 38 

 
accordance with Section 409A of the Code, including, where applicable, the requirement that (i) any reimbursement is for expenses incurred during
Dr. Goldenberg’s lifetime (or during a shorter time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other
calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the taxable year following the year in which the expense is incurred, and (iv) the right to reimbursement is not subject to liquidation
or exchange for another benefit. 
 18. Captions; Word Meanings. Captions contained in this Agreement are inserted only as a matter of
convenience and in no way define, limit or extend the scope of this Agreement or any provision hereof. The words “hereby”, “herein”, “hereinabove”, “hereinafter”, “hereof” and “hereunder”,
when used anywhere in this Agreement, refer to this Agreement as a whole and not merely to a subdivision in which such words appear, unless the context otherwise requires. The singular shall include the plural, the conjunctive shall include the
disjunctive and the masculine gender shall include the feminine and neuter, and vice versa, unless the context otherwise requires. 
 19.
Miscellaneous. 
 (a) Proration. Wherever in this Agreement there is provision for proration of Annual Net Sales
or any other calculation for any partial fiscal year, such proration shall be effected by multiplying the total Annual Net Sales or other annualized figure as the case may be, by a fraction, the numerator of which shall be the actual number of days
included in such partial fiscal year and the denominator of which shall be 365. 
 (b) Offsets. Wherever provision is
made in this Agreement for the payment of any amounts by one party hereto to another, such amounts either may be paid directly by the party obligated to make the payments to the other party or, at the option of the party obligated to make such
payments and with the consent of the other party, the obligated party may offset the amounts it is obligated to pay against all or part of any amounts owed that the other party is obligated to pay the first party, pursuant to or in connection with
this Agreement. 
  

 39 

 20. Binding Effect. This Agreement and all the terms and provisions hereof shall be binding upon
and shall inure to the benefit of the parties, their respective legal representatives, heirs, successors and permitted assigns. 
 21.
Entire Agreement. This Agreement, together with the documents specifically referenced herein, each of which is incorporated by reference and be governed by the provisions of this Agreement constitutes the entire agreement between the parties.
This Agreement supersedes and replaces the Initial Agreement, the Amended Agreements, and any other prior agreement or understandings between Dr. Goldenberg and Immunomedics on any subject covered by this Agreement. This Agreement may not be
modified or amended in any manner other than in writing executed by or on behalf of both parties on a date subsequent to the date of this Agreement. 
 22. Severability. If an arbitrator or court of competent jurisdiction should determine that any provision of this Agreement is overly broad in scope or duration, prohibited or unenforceable, the parties may
meet and attempt to reach agreement on a mutually acceptable modification that would be enforceable. If the parties cannot reach agreement on a modification within a reasonable time period, the arbitrator or court shall have the authority to modify
that portion of the Agreement only to the minimal extent possible to make it legally enforceable, and the balance of the Agreement shall remain in force without regard for the prohibited portion. 
 23. Survival of Provisions. The provisions of Sections 4.1, 4.2, 5, 7, 8 through 13, 15, 16, 17, 19, 22 and 23 of this Agreement, and the
provisions of any agreement incorporated by reference herein, shall survive expiration of the term or termination of employment for any reason. 
  

 40 

 24. Counterparts. This Agreement is written in the English language and may be executed in any
number of English language counterparts and each such duplicate counterpart shall constitute an original, any one of which may be introduced in evidence or used for any other purpose without the production of its duplicate counterpart. Moreover,
notwithstanding that any of the parties did not execute the same counterpart, each counterpart shall be deemed for all purposes to be an original, and all such counterparts shall constitute one and the same instrument, binding on all of the parties
hereto. 
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the day, month and year first above written. 
  

									
	Attest:	 		 	IMMUNOMEDICS, INC.
		 		 	(“Immunomedics”)
					
		 	/s/ Phyllis Parker	 		 	By: 	 	/s/ Gerard G. Gorman
		 	Secretary	 		 		 	Gerard G. Gorman
		 		 		 		 	 Senior Vice President, Finance and
 Business
Development, and Chief
 Financial Officer

			
	Witness:	 		 	
					
		 	/s/ Nancy Carey	 		 		 	/s/ David M. Goldenberg
		 		 		 		 	Dr. David M. Goldenberg
		 		 		 		 	(“Dr. Goldenberg”)

  

 41Second Amended and Restated Employment Agreement

 Exhibit 10.2 
 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT 
 THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into this 17th day of December, 2008 by and
between Immunomedics, Inc., a Delaware corporation having its principal offices in Morris Plains, New Jersey (the “Company”), and Cynthia L. Sullivan (the “Executive”). 
 WHEREAS, the Executive is presently employed by the Company in the capacity of President and Chief Executive Officer, pursuant to an Amended and Restated
Employment Agreement between the Company and Executive (the “Prior Employment Agreement”), dated December 31, 2006 (the “Effective Date”); 
 WHEREAS, the Company desires to continue to employ the Executive as its President and Chief Executive Officer, and the Executive desires to continue to serve in such capacity on behalf of the Company, upon the terms
and conditions hereinafter set forth; 
 WHEREAS, the Company and the Executive desire to amend and restate the terms and conditions of the
Prior Agreement in order to bring those terms and conditions into documentary compliance with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the final Treasury Regulations thereunder and continue
Executive’s employment with the Company upon the amended and restated terms and conditions of this Agreement; 
 WHEREAS, the Executive
acknowledges that she has had an opportunity to consider this Agreement and consult with an independent advisor(s) of her choosing with regard to the terms of this Agreement, and enters into this Agreement voluntarily and with a full understanding
of its terms; and 
 WHEREAS, the Company and the Executive have agreed that this Agreement will supercede and replace the Prior Employment
Agreement as of the Effective Date. 
  

 1 

 NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby agree as follows: 

1.1 Term. The term of this Agreement (the “Term”) shall begin as of the Effective Date and shall terminate on December 31, 2008,
unless sooner terminated by either party as hereinafter provided; provided, however, that the Term shall automatically be extended for successive one-year periods beginning on December 31, 2008 and on each subsequent anniversary thereof unless,
not later than 180 days preceding the date of any such extension, either party gives the other party written notice of such party’s intention not to further extend the Term. If the Company elects not to renew the Agreement, the Agreement will
continue in effect according to its terms until the end of the then current Term, at which time the Agreement shall terminate, with the exception of the Executive’s obligations set forth in Sections 4, 5, 6 and 7. The expiration or non-renewal
of this Agreement shall be deemed a termination of the Executive’s employment for purposes of this Agreement, including a termination without Cause for purposes of Section 2. 
 1.2 Duties and Responsibilities. Commencing on the Effective Date, Executive shall continue to serve as the President and Chief Executive Officer
of the Company and shall perform all duties and accept all responsibilities incident to such position as may be reasonably assigned to Executive by the Company’s Board of Directors (the “Board”). 
 1.3 Extent of Service. Executive agrees to use Executive’s best efforts to carry out Executive’s duties and responsibilities under
Section 1.1 hereof and, consistent with the other provisions of this Agreement, to devote substantially all of Executive’s business time, attention and energy thereto. The foregoing shall not be construed as preventing Executive from
making investments in other businesses or enterprises, provided that Executive agrees not to become engaged in any other business activity which, in the reasonable judgment of the Board, is likely to interfere with Executive’s ability to
discharge Executive’s duties and responsibilities to the Company. 
 1.4 Base Salary. For all the services rendered by Executive
hereunder, the Company shall pay Executive a base salary (“Base Salary”) at the annual rate of $532,000, payable bi-weekly in installments at such times as the Company customarily pays its other senior level executives. Executive’s
Base Salary shall be reviewed annually for appropriate increases by the Board or Compensation Committee of the Board (the “Compensation Committee”) pursuant to the normal performance review policies for senior level executives. 

1.5 Annual Bonus. During the Term, the Executive shall be eligible to participate in the Company’s incentive compensation plan in place
from time to time for its senior level executives generally, at levels determined by the Compensation Committee. The Company reserves the right to amend or rescind the incentive compensation plan at any time in its discretion. In connection with
Executive’s participation in the incentive compensation plan, the Executive shall be eligible to receive an annual discretionary bonus. The amount of the annual discretionary bonus, if any, will be determined by the Compensation Committee in
its discretion, based on the Executive’s individual performance and Company performance as determined by the Compensation Committee. The Executive’s annual bonus target is 30% of Base Salary, subject to achievement of performance goals to
be established by the Compensation Committee, with a potential payout from 0 to 150% of the target amount depending upon achievement of the performance goals. The discretionary annual bonus, if any, will be determined as of the end of 

  

 2 

 
each fiscal year during the Term and shall be payable as soon as practicable after the end of each fiscal year to which the bonus relates, but in no event,
later than 2-1/2 months after the end of such fiscal year, except as provided in Section 2. Except as otherwise specifically provided in Section 2, to be eligible to receive an annual bonus, or any portion thereof, the Executive must be
employed by the Company both at the time the amount of the annual bonus, if any, is determined, and at the time the annual bonus, if any, is to be paid. 
 1.6 Equity Compensation. During the Term, pursuant to the terms and conditions of the Company’s 2006 Stock Incentive Plan or any successor equity compensation plan as may be in place from time to time, the
Executive shall be eligible to receive, from time to time, awards in amounts, and subject to such terms, conditions and restrictions, as determined by the Compensation Committee in its sole discretion. Awards granted to the Executive, if any, shall
be subject to the terms and conditions established within the Company’s 2006 Stock Incentive Plan (as amended from time to time) or any successor equity compensation plan as may be in place from time to time, as applicable, and the separate
option agreement, restricted stock purchase agreement or stock award agreement between the Company and the Executive that sets forth the terms and conditions of the award (e.g., exercise price, expiration date and vesting schedule of stock
options; and the restricted period and/or other restrictions such as performance objectives relating to stock awards). 
 1.7 Retirement
and Welfare Plans. During the Term, Executive shall participate in employee retirement and welfare benefit plans made available to the Company’s senior level executives as a group or to its employees generally, as such retirement and
welfare plans may be in effect from time to time and subject to the eligibility requirements of the plans. Nothing in this Agreement shall prevent the Company from amending or terminating any retirement, welfare or other employee benefit plans or
programs from time to time as the Company deems appropriate. 
 1.8 Reimbursement of Expenses; Vacation. During the Term, Executive
shall be provided with reimbursement of reasonable expenses related to Executive’s employment by the Company on a basis no less favorable than that which may be authorized from time to time for senior level executives as a group, and shall be
entitled to six (6) weeks of vacation in accordance with the Company’s pay for time not worked policies. 
 1.9 Perquisites.
During the Term, Executive shall also be provided with executive fringe benefits and perquisites under the same terms as those made available to the Company’s senior level executives as a group, as such programs may be in effect from time to
time. Nothing in this Agreement or otherwise shall prevent the Company from amending or terminating any fringe benefits or perquisites from time to time as the Company deems appropriate. 
  

 3 

 2. Termination. Executive’s employment shall terminate upon the occurrence of any of the following events:

 2.1 Termination Without Cause or Resignation for Good Reason Before A Change of Control. 
 (a) The Company may remove Executive at any time without Cause (as defined in Section 2.9) from the position in which Executive is
employed hereunder upon not less than 30 days’ prior written notice to Executive. The Company shall have discretion to terminate Executive’s employment during the notice period and pay continued Base Salary in lieu of notice. In addition,
Executive may initiate a termination of employment by resigning under this Section 2.1 for Good Reason (as defined in Section 2.9), upon not less than 30 days’ prior written notice of such resignation. 
 (b) If Executive’s employment terminates as described in subsection (a) above and Executive executes and does not revoke a
written release upon such removal, in a form provided by the Company, of any and all claims against the Company and all related parties with respect to all matters arising out of Executive’s employment by the Company, or the termination thereof
(the “Release”), Executive shall be entitled to receive the following severance compensation, as long as Executive complies with the terms of Sections 4, 5, 6 and 7 below: 
 (i) Executive shall receive severance payments in an amount equal to the sum of: (x) being 2.00 times Executive’s annual Base
Salary at the rate in effect at the time of Executive’s termination, and (y) being Executive’s target bonus established for the fiscal year in which the date of termination occurs. The severance amount shall be paid in separate equal
monthly payments over the 24-month period following Executive’s termination of employment. 
 (ii) The Company shall, for
a period of 24 months following the date of Executive’s termination of employment, pay Executive each month an amount equal to the monthly COBRA medical insurance cost under the Company’s medical plan for Executive, and, where applicable,
her spouse and dependents, less an amount equal to the required monthly employee payment for such coverage calculated as if Executive had continued to be an employee of the Company throughout such period. 
 (iii) Executive shall receive any benefits accrued in accordance with the terms of any applicable benefit plans and programs of the
Company. In addition, Executive shall be entitled to the annual bonus, if any, payable for the fiscal year in which the termination occurs (prorated to reflect Executive’s actual period of service during such fiscal year) without regard to the
last sentence of Section 1.5. 
 (iv) Except as otherwise required by Section 2.10, the benefits described in
subsections (i) and (ii) above shall begin within 30 days after Executive’s termination date (or at the end of the revocation period for the Release, if later). The Company shall provide the Release to Executive on or before the
termination date, and Executive shall execute the Release during the time period permitted by applicable law.  
 (v)
Executive agrees that if Executive fails to comply with Section 4, 5, 6 or 7 below, all payments under this Section 2.1 shall immediately cease. 
  

 4 

 2.2 Termination Without Cause or Resignation for Good Reason After A Change of Control.

 (a) If a Change of Control occurs and, during the one-year period commencing on the date of the Change of Control, the
Company terminates Executive’s employment without Cause or Executive resigns for Good Reason (as defined in Section 2.9), this Section 2.2 shall apply. 
 (b) If Executive’s employment terminates as described in subsection (a) above and Executive executes and does not revoke a
Release, Executive shall be entitled to receive the following severance compensation, as long as Executive complies with the terms of Sections 4, 5, 6 and 7 below: 
 (i) Executive shall receive a lump sum severance payment in an amount equal to 3.00 times the sum of Executive’s annual Base Salary
at the rate in effect at the time of Executive’s termination and Executive’s target bonus for the calendar year in which the date of termination occurs. 
 (ii) The Company shall, for a period of 36 months following the date of Executive’s termination of employment, pay Executive each
month an amount equal to the monthly COBRA medical insurance cost under the Company’s medical plan for Executive, and, where applicable, her spouse and dependents, less an amount equal to the required monthly employee payment for such coverage
calculated as if Executive had continued to be an employee of the Company throughout such period. 
 (iii) Executive shall
receive any benefits accrued in accordance with the terms of any applicable benefit plans and programs of the Company. In addition, Executive shall be entitled to the annual bonus, if any, payable for the fiscal year in which the termination occurs
(prorated to reflect Executive’s actual period of service during such fiscal year) without regard to the last sentence of Section 1.5. 
 (iv) Except as otherwise required by Section 2.10, the lump sum payment described in subsection (i) shall be made, and the monthly payments described in subsection (ii) above shall begin, within 30 days
after Executive’s termination date (or at the end of the revocation period for the Release, if later). The Company shall provide the Release to Executive on or before the termination date, and Executive shall execute the Release during the time
period permitted by applicable law.  
 (c) Notwithstanding any provision to the contrary in the Company’s 2006
Stock Incentive Plan or any applicable plan, program or agreement, upon the occurrence of a Change of Control, all stock options, restricted stock and other equity rights held by the Executive will become fully vested and/or exercisable, as the case
may be, on the date on which the Change in Control occurs, and all stock options held by the Executive shall remain exercisable, notwithstanding anything in any other agreement governing such options, for a period of twenty-four (24) months
following the end of the remaining balance of the Term of the Agreement; provided, however, that in no event will the option be exercisable (a) beyond its original term; or (b) beyond the extension period permitted under Section 409A
of the Code. 
  

 5 

 (d) Notwithstanding any provision to the contrary in any applicable plan, program or
agreement providing for supplemental retirement benefits or deferred compensation, upon the occurrence of a Change of Control, Executive’s accrued benefit under such plans, programs or agreements shall become fully vested on the date on which
the Change in Control occurs, and shall be immediately payable on the Executive’s date of termination, unless the Executive has made a valid election under such plan, program or agreement to defer payment of such accrued benefits. 

(e) Executive agrees that if Executive materially breaches Section 4, 5, 6 or 7 below, all payments and benefits under this
Section 2.2 shall immediately cease. 
 2.3 Increase in Payments Upon a Change of Control. 
 (a) Anything in this Agreement to the contrary notwithstanding, in the event that it shall be determined that any payment or distribution
by the Company to or for the benefit of Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise (a “Payment”), would constitute an “excess parachute payment” within
the meaning of Section 280G of the Code, the Company shall pay to Executive an additional amount (the “Gross-Up Payment”) such that the net amount retained by Executive after deduction of any excise tax imposed under Section 4999
of the Code, and any federal, state and local income tax, employment tax and excise tax imposed upon the Gross-Up Payment, shall be equal to the Payment. For purposes of determining the amount of the Gross-Up Payment, unless Executive specifies that
other rates apply, Executive shall be deemed to pay federal income tax and employment taxes at the highest marginal rate of federal income and employment taxation in the calendar year in which the Gross-Up Payment is to be made and state and local
income taxes at the highest marginal rate of taxation in the state and locality of Executive’s residence on Executive’s termination date, net of the maximum reduction in federal income taxes that may be obtained from the deduction of such
state and local taxes. 
 (b) All determinations to be made under this Section 2.3 shall be made by the Company’s
independent public accountant immediately prior to the Change of Control or by another independent public accounting firm mutually selected by the Company and Executive before the date of the Change of Control (the “Accounting Firm”),
which firm shall provide its determinations and any supporting calculations both to the Company and Executive within 20 days after Executive’s termination date. Any such determination by the Accounting Firm shall be binding upon the Company and
Executive. 
 (c) The Company shall pay the Gross-Up Payment as and when the related excise tax under section 4999 of the Code
(“Excise Tax”) is incurred. The Gross-Up Payment shall be paid in accordance with Section 409A of the Code, to the extent applicable. If required in order to comply with Section 409A of the Code, (i) the Gross-Up Payment
attributable to Payments other than severance compensation shall be paid in a lump sum payment upon the closing of the Change of Control, subject to Section 2.10 below, if applicable, and (ii) the Gross-Up Payment attributable to severance
compensation shall be paid in a lump sum payment on the first day on which severance compensation is paid. If the amount of a Gross-Up Payment cannot be fully determined by the date on which the applicable portion of the Payment becomes subject to
the Excise Tax (“Payment Date”), the Company shall pay to the Employee by the Payment 

  

 6 

 
Date an estimate of such Gross-Up Payment, as determined by the Accounting Firm, and the Company shall pay to the Employee the remainder of such Gross-Up
Payment (if any) as soon as the amount can be determined, but in no event later than 20 days after the Payment Date. 
 (d)
All of the fees and expenses of the Accounting Firm in performing the determinations referred to in this Section 2.3 shall be borne solely by the Company. The Company agrees to indemnify and hold harmless the Accounting Firm from any and all
claims, damages and expenses resulting from or relating to its determinations pursuant to this Section 2.3, except for claims, damages or expenses resulting from the gross negligence or willful misconduct of the Accounting Firm. 
 2.4 Voluntary Termination. Executive may voluntarily terminate Executive’s employment for any reason upon 30 days’ prior written notice.
In such event, after the effective date of such termination, except as provided in Section 2.2 with respect to a resignation for Good Reason, no further payments shall be due under this Agreement, except that Executive shall be entitled to any
benefits accrued in accordance with the terms of any applicable benefit plans and programs of the Company. 
 2.5 Disability. The
Company may terminate Executive’s employment if Executive has been unable to perform the material duties of Executive’s employment for a period of 90 days in any 12-month period because of physical or mental injury or illness
(“Disability”); provided, however, that the Company shall continue to pay Executive’s Base Salary until the Company acts to terminate Executive’s employment. Notwithstanding the foregoing, the Executive shall be deemed terminated
for Disability if the Executive is disabled for a period of 12 months. Executive agrees, in the event of a dispute under this Section 2.5 relating to Executive’s Disability, to submit to a physical examination by a licensed physician
jointly selected by the Board and Executive. If the Company terminates Executive’s employment for Disability, no further payments shall be due under this Agreement, except that Executive shall be entitled to any benefits accrued in accordance
with the terms of any applicable benefit plans and programs of the Company. In addition, Executive shall be entitled to the annual bonus, if any, payable for the fiscal year in which the termination occurs (prorated to the date Executive is
determined to have a Disability) without regard to the last sentence of Section 1.5. 
 2.6 Death. If Executive dies while
employed by the Company, the Company shall pay to Executive’s executor, legal representative, administrator or designated beneficiary, as applicable, any benefits accrued under the Company’s benefit plans and programs in accordance with
the terms and conditions contained therein. Otherwise, the Company shall have no further liability or obligation under this Agreement to Executive’s executors, legal representatives, administrators, heirs or assigns or any other person claiming
under or through Executive. In addition, Executive shall be entitled to the annual bonus, if any, payable for the fiscal year in which the termination occurs (prorated to reflect Executive’s actual period of service during such fiscal year)
without regard to the last sentence of Section 1.5. 
 2.7 Cause. The Company may terminate Executive’s employment at any
time for Cause (as defined in Section 2.9) upon written notice to Executive, in which event all payments under this Agreement shall cease. Executive shall be entitled to any benefits accrued before Executive’s termination in accordance
with the terms of any applicable benefit plans and programs of the Company. 
  

 7 

 2.8 Notice of Termination. Any termination of Executive’s employment shall be communicated by
a written notice of termination to the other party hereto given in accordance with Section 11. The notice of termination shall (i) indicate the specific termination provision in this Agreement relied upon, (ii) briefly summarize the
facts and circumstances deemed to provide a basis for a termination of employment and the applicable provision hereof, and (iii) specify the termination date in accordance with the requirements of this Agreement. 
 2.9 Definitions. 
 (a)
“Cause” shall mean any of the following grounds for termination of Executive’s employment: 
 (i)
Executive shall have been convicted of a felony, or enters in a plea of guilty or nolo contendere with respect thereto; 
 (ii) Executive intentionally and continually fails to perform Executive’s reasonably assigned material duties to the Company (other than a failure resulting from Executive’s incapacity due to physical or mental illness), which
failure has continued for a period of at least 30 days after a written notice of demand for substantial performance, signed by a duly authorized officer of the Company, has been delivered to Executive specifying the manner in which Executive has
failed substantially to perform; 
 (iii) Executive causes material, intentional, wrongful damage to the property of the
Company; 
 (iv) Executive engages in public conduct that is harmful to the reputation of the Company; 
 (v) Executive engages in willful misconduct in the performance of Executive’s duties; or 
 (vi) Executive materially breaches Sections 4, 5, 6 or 7 below. 
 (b) “Change of Control” shall mean: 
 (i) A merger, consolidation or reorganization approved by the Company’s stockholders, unless securities representing more than fifty
percent (50%) of the total and combined voting power of the outstanding voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly, by the persons who beneficially owned the
Company’s outstanding voting securities immediately prior to such transaction; or 
 (ii) The sale, transfer or other
disposition of all or substantially all of the Company’s assets as an entirety or substantially as an entirety, occurring within a 12-month period, and representing, at a minimum, not less than 40 percent of the total gross fair 

  

 8 

 
market value of all assets of the Company, to any person, entity, or group of persons acting in consort, other than a sale, transfer or disposition to:
(A) a shareholder of the Company in exchange for or with respect to its stock; (B) an entity, 50 percent or more of the total value or voting power of which is owned, directly or indirectly, by the Company; (C) a person, or more than
one person acting as a group, that owns, directly or indirectly, 50 percent or more of the total value or voting power of the outstanding stock of the Company; or (D) an entity, at least 50 percent of the total value or voting power of which is
owned by a person described in (C); or 
 (iii) Any transaction or series of related transactions pursuant to which any person
or any group of persons comprising a “group” within the meaning of Rule 13d-5(b)(1) under the Securities Exchange Act of 1934, as amended (other than the Company or a person that, prior to such transaction or series of related
transactions, directly or indirectly controls, is controlled by or is under common control with, the Company) becomes directly or indirectly the beneficial owner (within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended)
of securities possessing (or convertible into or exercisable for securities possessing) more than fifty percent (50%) of the total combined voting power of the Company’s securities outstanding immediately after the consummation of such
transaction or series of related transactions, whether such transaction involves a direct issuance from the Company or the acquisition of outstanding securities held by one or more of the Company’s stockholders; or 
 (iv) A change in the composition of the Board over a period of twelve (12) consecutive months or less such that a majority of the
Board members ceases by reason of one or more contested elections for Board membership to be comprised of individuals whose election is endorsed by a majority of the members of the Board immediately before the date of election. 
 A transaction shall not constitute a Change of Control if its sole purpose is to change the state of the Company’s incorporation or to create a holding company that
will be owned in the same proportions by the persons who held the Company’s securities immediately before such transaction. 
 (c) “Code” shall mean the Internal Revenue Code of 1986, as amended. 
 (d) “Good Reason”
shall mean the occurrence of any of the following events or conditions, unless Executive has expressly consented in writing thereto, or except as a result of Executive’s physical or mental incapacity or as described in the last sentence of this
subsection (d): 
 (i) A material reduction in Executive’s Base Salary; 
 (ii) The material diminution of the Executive’s duties, responsibilities, powers or authorities, including the assignment of any
duties and responsibilities inconsistent with her position as President and Chief Executive Officer; or 
 (iii) The Company
requires that Executive’s principal office location be moved to a location more than 50 miles form Executive’s principal office location immediately before the change. 
  

 9 

 Notwithstanding the foregoing, Executive shall not have Good Reason for termination unless Executive gives written notice
of termination for Good Reason within 15 days after the event giving rise to Good Reason occurs and the Company does not correct the action or failure to act that constitutes the grounds for Good Reason, as set forth in Executive’s notice of
termination, within 30 days after the date on which Executive gives written notice of termination. 
 2.10 Required Postponement for
Specified Executives. 
 (a) If Executive is considered a Specified Executive (as defined below) and payment of any
amounts under this Agreement is required to be delayed for a period of six months after separation from service pursuant to Section 409A of the Code, payment of such amounts shall be delayed as required by section 409A, and the accumulated
postponed amounts, with accrued interest as described below, shall be paid in a lump sum payment within five days after the end of the six month period. If Executive dies during the postponement period prior to the payment of benefits, the amounts
postponed on account of Section 409A, with accrued interest as described in subsection (b) below, shall be paid to the personal representative of Executive’s estate within 60 days after the date of Executive’s death. 

(b) If payment of any amounts under this Agreement is required to be delayed pursuant to section 409A of the Code, the Company shall
pay interest on the postponed payments from the date on which the amounts otherwise would have been paid to the date on which such amounts are paid at an annual rate equal to the rate published in the Wall Street Journal as the “prime
rate” as of Executive’s date of termination. 
 (c) The term “Specified Executive” means an employee who,
at any time during the 12-month period ending on the identification date (defined below), is (i) an officer of the Company or a member of its controlled group (as determined for purposes of section 416(i) of the Code) who has annual
compensation greater than $135,000 (or such other amount as may be in effect under Section 416(i)(1) of the Code), (ii) a 5% owner of the Company or (iii) a 1% owner of the Company who has annual compensation greater than $150,000.
The identification date shall be each December 31, and the determination of Specified Executives as of such identification date shall apply for the 12-month period following April 1 after the identification date. The determination of
Specified Executives, including the number and identity of persons considered officers, shall be made by the Company in accordance with the provisions of Sections 416(i) and 409A of the Code and the regulations issued thereunder. 
 3. Non-Exclusivity of Rights. Nothing in this Agreement shall prevent or limit Executive’s continuing or future participation in or rights under any benefit,
bonus, incentive or other plan or program provided by the Company and for which Executive may qualify; provided, however, that if Executive becomes entitled to and receives the payments provided for in Section 2 of this Agreement, Executive
hereby waives Executive’s right to receive payments under any severance plan or similar program applicable to all employees of the Company. 
 4.
Confidentiality. Executive agrees that Executive’s services to the Company and its subsidiaries and any successors or assigns (collectively, the “Employer”) were and are of a special, unique and extraordinary character, and
that Executive’s position places Executive in a position of confidence and trust with the Employer’s customers and employees. Executive also 

  

 10 

 
recognizes that Executive’s position with the Employer will give Executive substantial access to Confidential Information (as defined below), the
disclosure of which to competitors of the Employer would cause the Employer to suffer substantial and irreparable damage. Executive recognizes, therefore, that it is in the Employer’s legitimate business interest to restrict Executive’s
use of Confidential Information for any purposes other than the discharge of Executive’s employment duties at the Employer, and to limit any potential appropriation of Confidential Information by Executive for the benefit of the Employer’s
competitors and to the detriment of the Employer. Accordingly, Executive agrees as follows: 
 (a) Executive will not at any
time, whether during or after the termination of Executive’s employment, reveal to any person or entity any of the trade secrets or confidential information of the Employer or of any third party which the Employer is under an obligation to keep
confidential (including but not limited to trade secrets or confidential information respecting inventions, products, designs, methods, know-how, techniques, systems, processes, software programs, works of authorship, customer lists, projects, plans
and proposals) (“Confidential Information”), except as may be required in the ordinary course of performing Executive’s duties as an employee of the Employer, and Executive shall keep secret all matters entrusted to Executive and
shall not use or attempt to use any such information in any manner which may injure or cause loss or may be calculated to injure or cause loss whether directly or indirectly to the Employer. 
 (b) The above restrictions shall not apply to: (i) information that at the time of disclosure is in the public domain through no
fault of Executive; (ii) information received from a third party outside of the Employer that was disclosed without a breach of any confidentiality obligation; (iii) information approved for release by written authorization of the
Employer; or (iv) information that may be required by law or an order of any court, agency or proceeding to be disclosed; provided Executive shall provide the Employer notice of any such required disclosure once Executive has knowledge of it
and will help the Employer to the extent reasonable to obtain an appropriate protective order. 
 (c) Further, Executive
agrees that during Executive’s employment Executive shall not take, use or permit to be used any notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, data, documentation or other materials of any
nature relating to any matter within the scope of the business of the Employer or concerning any of its dealings or affairs otherwise than for the benefit of the Employer. Executive further agrees that Executive shall not, after the termination of
Executive’s employment, use or permit to be used any such notes, memoranda, reports, lists, records, drawings, sketches, specifications, software programs, data, documentation or other materials, it being agreed that all of the foregoing shall
be and remain the sole and exclusive property of the Employer and that, immediately upon the termination of Executive’s employment, Executive shall deliver all of the foregoing, and all copies thereof, to the Employer, at its main office.

 (d) Executive agrees that upon the termination of Executive’s employment with the Employer, Executive will not take or
retain without written authorization any documents, files or other property of the Employer, and Executive will return promptly to the Employer any such documents, files or property in Executive’s possession or custody, including 

  

 11 

 
any copies thereof maintained in any medium or format. Executive recognizes that all documents, files and property which Executive has received and will
receive from the Employer, including but not limited to scientific research, customer lists, handbooks, memoranda, product specifications, and other materials (with the exception of documents relating to benefits to which Executive might be entitled
following the termination of Executive’s employment with the Employer), are for the exclusive use of the Employer and employees who are discharging their responsibilities on behalf of the Employer, and that Executive has no claim or right to
the continued use, possession or custody of such documents, files or property following the termination of Executive’s employment with the Employer. 
 5. Intellectual Property. 
 (a) If at any time or times during Executive’s employment Executive shall
(either alone or with others) make, conceive, discover or reduce to practice any invention, modification, discovery, design, development, improvement, process, software program, work of authorship, documentation, formula, data, technique, know-how,
secret or intellectual property right whatsoever or any interest therein (whether or not patentable or registrable under copyright or similar statutes or subject to analogous protection) (herein called “Developments”) that (i) relates
to the business of the Employer or any customer of or supplier to the Employer or any of the products or services being developed, manufactured or sold by the Employer or which may be used in relation therewith, (ii) results from tasks assigned
to Executive by the Employer or (iii) results from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Employer, such Developments and the benefits thereof shall immediately become
the sole and absolute property of the Employer and its assigns, and Executive shall promptly disclose to the Employer (or any persons designated by it) each such Development, and Executive hereby assigns any rights Executive may have or acquire in
the Developments and benefits and/or rights resulting therefrom to the Employer and its assigns without further compensation and shall communicate, without cost or delay, and without publishing the same, all available information relating thereto
(with all necessary plans and models) to the Employer. 
 (b) Upon disclosure of each Development to the Employer, Executive
will, during Executive’s employment and at any time thereafter, at the request and cost of the Employer, sign, execute, make and do all such deeds, documents, acts and things as the Employer and its duly authorized agents may reasonably
require: 
 (i) to apply for, obtain and vest in the name of the Employer alone (unless the Employer otherwise directs)
letters patent, copyrights or other analogous protection in any country throughout the world and when so obtained or vested to renew and restore the same; and 
 (ii) to defend any opposition proceedings in respect of such applications and any opposition proceedings or petitions or applications for
revocation of such letters patent, copyright or other analogous protection. 
  

 12 

 (c) In the event the Employer is unable, after reasonable effort, to secure
Executive’s signature on any letters patent, copyright or other analogous protection relating to a Development, whether because of Executive’s physical or mental incapacity or for any other reason whatsoever, Executive hereby irrevocably
designates and appoints the Employer and its duly authorized officers and agents as Executive’s agent and attorney-in-fact, to act for and on Executive’s behalf and stead to execute and file any such application or applications and to do
all other lawfully permitted acts to further the prosecution and issuance of letter patents, copyright and other analogous protection thereon with the same legal force and effect as if executed by Executive. 
 6. Non-Competition. While Executive is employed at the Employer and for a period of two (2) years after termination of Executive’s employment (for any
reason whatsoever, whether voluntary or involuntarily), Executive will not, without the prior written approval of the Board, whether alone or as a partner, officer, director, consultant, agent, employee or stockholder of any company or other
commercial enterprise, directly or indirectly engage in any business or other activity in the United States or Canada which competes with the Employer in the field of therapeutic antibodies for cancer. The foregoing prohibition shall not prevent
Executive’s employment or engagement after termination of Executive’s employment by any company or business organization, as long as the activities of any such employment or engagement, in any capacity, do not involve work on matters
related to the products being developed, manufactured, or marketed by the Employer during Executive’s employment with the Employer. Executive shall be permitted to own securities of a public company not in excess of five percent of any class of
such securities and to own stock, partnership interests or other securities of any entity not in excess of five percent of any class of such securities and such ownership shall not be considered to be in competition with the Employer. 
 7. Non-Solicitation. While Executive is employed at the Employer and for a period of two (2) years after termination of such employment (for any reason,
whether voluntary or involuntarily), Executive agrees that Executive will not: 
 (a) directly or indirectly solicit, entice
or induce any customer to become a customer of any other person, firm or corporation with respect to products then sold or under development by the Employer or to cease doing business with the Employer, and Executive shall not approach any such
person, firm or corporation for such purpose or authorize or knowingly approve the taking of such actions by any other person; or 
 (b) directly or indirectly solicit or recruit any employee of the Employer to work for a third party other than the Employer (excluding newspaper or similar print or electronic solicitations of general circulation). 
 8. General Provisions. 
 (a) Executive
acknowledges and agrees that the type and periods of restrictions imposed in Sections 4, 5, 6 and 7 of this Agreement are fair and reasonable, and that such restrictions are intended solely to protect the legitimate interests of the Employer, rather
than to prevent Executive from earning a livelihood. Executive recognizes that the Employer competes worldwide, and that Executive’s access to Confidential Information makes it necessary for the Employer to restrict Executive’s
post-employment activities in any market in which the Employer competes, and in which Executive’s access to Confidential Information and other 

  

 13 

 
proprietary information could be used to the detriment of the Employer. In the event that any restriction set forth in this Agreement is determined to be
overbroad with respect to scope, time or geographical coverage, Executive agrees that such a restriction or restrictions should be modified and narrowed, either by a court or by the Employer, so as to preserve and protect the legitimate interests of
the Employer as described in this Agreement, and without negating or impairing any other restrictions or agreements set forth herein. 
 (b) Executive acknowledges and agrees that if Executive should breach any of the covenants, restrictions and agreements contained herein, irreparable loss and injury would result to the Employer, and that damages
arising out of such a breach may be difficult to ascertain. Executive therefore agrees that, in addition to all other remedies provided at law or at equity, the Employer shall be entitled to have the covenants, restrictions and agreements contained
in Sections 4, 5, 6, and 7 specifically enforced (including, without limitation, by temporary, preliminary, and permanent injunctions and restraining orders) by any state or federal court in the State of New Jersey having equity jurisdiction and
Executive agrees to subject Executive to the jurisdiction of such court. 
 (c) Executive agrees that if the Employer fails to
take action to remedy any breach by Executive of this Agreement or any portion of the Agreement, such inaction by the Employer shall not operate or be construed as a waiver of any subsequent breach by Executive of the same or any other provision,
agreement or covenant. 
 (d) Executive acknowledges and agrees that the payments and benefits to be provided to Executive
under this Agreement are provided as consideration for the covenants in Sections 4, 5, 6, and 7 hereof. 
 9. Survivorship. The respective rights and
obligations of the parties under this Agreement shall survive any termination of Executive’s employment to the extent necessary to the intended preservation of such rights and obligations. 
 10. Mitigation. Executive shall not be required to mitigate the amount of any payment or benefit provided for in this Agreement by seeking other employment or
otherwise and there shall be no offset against amounts due Executive under this Agreement on account of any remuneration attributable to any subsequent employment that Executive may obtain. 
 11. Notices. All notices and other communications required or permitted under this Agreement or necessary or convenient in connection herewith shall be in writing
and shall be deemed to have been given when hand delivered or mailed by registered or certified mail, as follows (provided that notice of change of address shall be deemed given only when received): 
 If to the Company, to: 
 Immunomedics, Inc. 
 300 American Road 
 Morris Plains, NJ 07950 
  

 14 

 If to Executive, to: 
 Cynthia L. Sullivan 
 or to such other names
or addresses as the Company or Executive, as the case may be, shall designate by notice to each other person entitled to receive notices in the manner specified in this Section. 
 12. Contents of Agreement; Amendment and Assignment. 
 (a) This Agreement sets forth
the entire understanding between the parties hereto with respect to the subject matter hereof and supercedes any and all prior agreements, including the Prior Employment Agreement, and understandings concerning Executive’s employment by the
Company and cannot be changed, modified, extended or terminated except upon written amendment approved by the Board and executed on its behalf by a duly authorized officer and by Executive. 
 (b) All of the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be enforceable by the
respective heirs, executors, administrators, legal representatives, successors and assigns of the parties hereto, except that the duties and responsibilities of Executive under this Agreement are of a personal nature and shall not be assignable or
delegatable in whole or in part by Executive. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) to all or substantially all of the business or assets of the Company,
within 15 days of such succession, expressly to assume and agree to perform this Agreement in the same manner and to the same extent as the Company would be required to perform if no such succession had taken place. 
 13. Severability. If any provision of this Agreement or application thereof to anyone or under any circumstances is adjudicated to be invalid or unenforceable in
any jurisdiction, such invalidity or unenforceability shall not affect any other provision or application of this Agreement which can be given effect without the invalid or unenforceable provision or application and shall not invalidate or render
unenforceable such provision or application in any other jurisdiction. If any provision is held void, invalid or unenforceable with respect to particular circumstances, it shall nevertheless remain in full force and effect in all other
circumstances. 
 14. Remedies Cumulative; No Waiver. No remedy conferred upon a party by this Agreement is intended to be exclusive of any other
remedy, and each and every such remedy shall be cumulative and shall be in addition to any other remedy given under this Agreement or now or hereafter existing at law or in equity. No delay or omission by a party in exercising any right, remedy or
power under this Agreement or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time to time and as often as may be deemed expedient or necessary by such
party in its sole discretion. 
  

 15 

 15. Withholding. All payments under this Agreement shall be made subject to applicable tax withholding, and the
Company shall withhold from any payments under this Agreement all federal, state and local taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation. Except as otherwise provided by Section 2.3,
Executive shall bear all expense of, and be solely responsible for, all federal, state and local taxes due with respect to any payment received under this Agreement. 
 16. Miscellaneous. This Agreement may be executed in counterparts, each of which is an original. It shall not be necessary in making proof of this Agreement or any counterpart hereof to produce or account for
any of the other counterparts. 
 17. Governing Law. This Agreement shall be governed by and interpreted under the laws of the State of New Jersey
without giving effect to any conflict of laws provisions or canons of construction that construe agreements against the draftsperson. 
 18.
Section 409A of the Code. This Agreement is intended to comply with Section 409A of the Code and its corresponding regulations, to the extent applicable. Notwithstanding anything in this Agreement to the contrary, payments may only
be made under this Agreement upon an event and in a manner permitted by Section 409A of the Code, to the extent applicable. For purposes of Section 409A of the Code, each payment made under this Agreement shall be treated as a separate
payment and the right to a series of installment payments shall be treated as the right to a series of separate payments. 
 [Signature
Page Follows] 
  

 16 

 IN WITNESS WHEREOF, the undersigned, intending to be legally bound, have executed this Agreement as of
the date first above written. 
  

			
	IMMUNOMEDICS, INC.
		
	By:	 	/s/ Gerard G. Gorman
	Name:	 	Gerard G. Gorman
	Title:	 	Senior Vice President, Finance and Business Development, and Chief Financial Officer

  

	
	EXECUTIVE
	
	/s/ Cynthia L. Sullivan
	Cynthia L. Sullivan

  

 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}]]